

# The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023



GBD 2023 Cancer Collaborators\*

## Summary

**Background** Cancer is a leading cause of death globally. Accurate cancer burden information is crucial for policy planning, but many countries do not have up-to-date cancer surveillance data. To inform global cancer-control efforts, we used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 framework to generate and analyse estimates of cancer burden for 47 cancer types or groupings by age, sex, and 204 countries and territories from 1990 to 2023, cancer burden attributable to selected risk factors from 1990 to 2023, and forecasted cancer burden up to 2050.

**Methods** Cancer estimation in GBD 2023 used data from population-based cancer registration systems, vital registration systems, and verbal autopsies. Cancer mortality was estimated using ensemble models, with incidence informed by mortality estimates and mortality-to-incidence ratios (MIRs). Prevalence estimates were generated from modelled survival estimates, then multiplied by disability weights to estimate years lived with disability (YLDs). Years of life lost (YLLs) were estimated by multiplying age-specific cancer deaths by the GBD standard life expectancy at the age of death. Disability-adjusted life-years (DALYs) were calculated as the sum of YLLs and YLDs. We used the GBD 2023 comparative risk assessment framework to estimate cancer burden attributable to 44 behavioural, environmental and occupational, and metabolic risk factors. To forecast cancer burden from 2024 to 2050, we used the GBD 2023 forecasting framework, which included forecasts of relevant risk factor exposures and used Socio-demographic Index as a covariate for forecasting the proportion of each cancer not affected by these risk factors. Progress towards the UN Sustainable Development Goal (SDG) target 3.4 aim to reduce non-communicable disease mortality by a third between 2015 and 2030 was estimated for cancer.

**Findings** In 2023, excluding non-melanoma skin cancers, there were 18·5 million (95% uncertainty interval 16·4 to 20·7) incident cases of cancer and 10·4 million (9·65 to 10·9) deaths, contributing to 271 million (255 to 285) DALYs globally. Of these, 57·9% (56·1 to 59·8) of incident cases and 65·8% (64·3 to 67·6) of cancer deaths occurred in low-income to upper-middle-income countries based on World Bank income group classifications. Cancer was the second leading cause of deaths globally in 2023 after cardiovascular diseases. There were 4·33 million (3·85 to 4·78) risk-attributable cancer deaths globally in 2023, comprising 41·7% (37·8 to 45·4) of all cancer deaths. Risk-attributable cancer deaths increased by 72·3% (57·1 to 86·8) from 1990 to 2023, whereas overall global cancer deaths increased by 74·3% (62·2 to 86·2) over the same period. The reference forecasts (the most likely future) estimate that in 2050 there will be 30·5 million (22·9 to 38·9) cases and 18·6 million (15·6 to 21·5) deaths from cancer globally, 60·7% (41·9 to 80·6) and 74·5% (50·1 to 104·2) increases from 2024, respectively. These forecasted increases in deaths are greater in low-income and middle-income countries (90·6% [61·0 to 127·0]) compared with high-income countries (42·8% [28·3 to 58·6]). Most of these increases are likely due to demographic changes, as age-standardised death rates are forecast to change by –5·6% (–12·8 to 4·6) between 2024 and 2050 globally. Between 2015 and 2030, the probability of dying due to cancer between the ages of 30 years and 70 years was forecasted to have a relative decrease of 6·5% (3·2 to 10·3).

**Interpretation** Cancer is a major contributor to global disease burden, with increasing numbers of cases and deaths forecasted up to 2050 and a disproportionate growth in burden in countries with scarce resources. The decline in age-standardised mortality rates from cancer is encouraging but insufficient to meet the SDG target set for 2030. Effectively and sustainably addressing cancer burden globally will require comprehensive national and international efforts that consider health systems and context in the development and implementation of cancer-control strategies across the continuum of prevention, diagnosis, and treatment.

**Funding** Gates Foundation, St Jude Children's Research Hospital, and St Baldrick's Foundation.

**Copyright** © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

Published Online  
September 24, 2025  
[https://doi.org/10.1016/S0140-6736\(25\)01635-6](https://doi.org/10.1016/S0140-6736(25)01635-6)  
See Online/Comment  
[https://doi.org/10.1016/S0140-6736\(25\)01570-3](https://doi.org/10.1016/S0140-6736(25)01570-3)

\*Collaborators listed at the end of the Article.

Correspondence to:  
Lisa M Force, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA 98195, USA  
[lforce@uw.edu](mailto:lforce@uw.edu)

### Research in context

#### Evidence before this study

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has produced estimates of cancer burden since its inception in 1993. Over time, additional cancer types have been separately estimated, with additional years of estimates produced for cancer incidence, mortality, years of life lost (YLLs), years lived with disability, and disability-adjusted life-years (DALYs) across global, regional, national, and select subnational geographies. For relevant cancer types, the burden attributable to potentially modifiable risk factors has also been estimated across time and geography. Another source of cancer estimates is the Global Cancer Observatory (GLOBOCAN) study from the International Agency for Research on Cancer, which generates estimates for cancer incidence and mortality in single years, with the most recent iteration providing estimates for 36 cancers for 2022. Cancer burden attributable to individual risk factors or groups of risk factors (eg, obesity, alcohol, and infections) are also produced for single years, although not in each GLOBOCAN round. In the current GLOBOCAN round, forecasts of cancer incidence and mortality are provided up to 2050. However, no other research enterprise besides GBD produces, on a regular basis, global estimates of cancer DALYs—a comprehensive measure that accounts for both the mortality and morbidity of cancers—or generates estimates for other disease groups (eg, cardiovascular diseases, respiratory infections, and tuberculosis) with consistent methodology, which allows for comparison of cancer burden to other diseases as part of policy and resource priority setting. For GBD 2023, we estimated cancer burden for 55 cancer types or groupings (47 of which are reported in this Article) from 1990 to 2023; generated estimates of risk-attributable cancer burden across

all relevant cancer types from 1990 to 2023; and forecasted cancer deaths, YLLs, and DALYs up to 2050.

#### Added value of this study

Our GBD 2023 study updates previous GBD round estimates of cancer burden and includes additional data and improvements in methods. We separately report for the first time comprehensive burden estimates for nine new cancer types: soft tissue and other extraosseous sarcomas, malignant neoplasms of the bone and articular cartilage, Burkitt lymphoma, other non-Hodgkin lymphoma, eye cancers (including separate estimates for retinoblastoma and other eye cancers), neuroblastoma and other malignant peripheral nervous cell tumours, and hepatoblastoma. Also, for the first time, we present forecasts of the trajectory of cancer burden up to 2050. These estimates can inform ongoing and future cancer-control efforts to address the growing challenge of cancer globally.

#### Implications of all the available evidence

Cancer is a major contributor to global disease burden, with inequitable burden weighing on low-income and lower-middle-income countries as their populations age. A substantial proportion of global cancer burden is attributable to known risk factors, which have the opportunity for mitigation through prevention efforts. Cancer burden continues to grow globally, and increasing cancer cases and deaths are expected in the coming decades. Addressing the continued and inequitable growth of cancer globally will require comprehensive and sustainable national and international efforts that consider the unique aspects of health systems and context in the development and implementation of cancer-control strategies.

### Introduction

Cancer is a major cause of death globally, affecting individuals and communities in every country.<sup>1,2</sup> The burden of cancer continues to grow globally,<sup>1</sup> increasing pressure on health systems across the world. In recognition of this expanding need, multiple *Lancet* commissions have focused on cancer and called for high-quality and equitable care.<sup>3–9</sup> WHO has established initiatives dedicated to improving global outcomes for specific cancer categories, including breast, cervical, and childhood cancers.<sup>10–12</sup> As part of the overarching goal of improving health and wellbeing, the UN Sustainable Development Goals (SDGs) established reducing premature mortality due to cancer and other non-communicable diseases (NCDs) as a target.<sup>13</sup> Crucial work is being done around the world to address the burden of cancer; however, most countries need to accelerate efforts to meet SDG target 3.4, which aims to “reduce by one-third premature mortality from NCDs”.<sup>13,14</sup> The COVID-19 pandemic created additional disruptions to achieving target reductions in cancer mortality, with many patients across the world experiencing challenges

in accessing screening programmes and necessary care for their cancer diagnoses.<sup>15–17</sup> There is growing evidence that the COVID-19 pandemic affected the number of cancer cases diagnosed in some countries, for select cancer types, and particularly in the early pandemic period.<sup>18</sup> Yet to be fully elucidated is the duration and generalisability of these diagnosis declines and the potential impact of the pandemic on cancer mortality. Any effect on cancer mortality might require time to become apparent and might further challenge the international ability to meet SDG target 3.4.

Cancers, referring to malignant and invasive neoplasms, include a broad spectrum of cancer types, with changes in epidemiology over the life course. There are rapidly evolving diagnostic and treatment opportunities for a subset of cancer types, but major disparities remain across the world in the cancer-control continuum, from risk factor exposures and mitigation to access to early diagnosis, high-quality treatment, and survivorship care.<sup>19–21</sup> Accurate cancer burden information is crucial to inform effective cancer-control policy, but cancer surveillance data are scarce or unavailable in many

countries. Furthermore, every country has multiple competing health priorities, underscoring the importance of contextualising the local burden of cancer compared with other diseases affecting a country's population. Two organisations routinely produce estimates of global cancer burden to address the gaps in cancer data that exist: the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) from the Institute for Health Metrics and Evaluation and its collaborators and the GLOBOCAN study from the International Agency for Research on Cancer.<sup>1,22</sup> Both studies use existing data sources to generate statistical estimates of cancer burden where data do not exist but differ in methodological choices and categories of estimates presented, with the GBD study presenting cancer burden estimates across expanded measures (including incidence, prevalence, mortality, years of life lost [YLLs], years lived with disability [YLDs], and disability-adjusted life-years [DALYs]) and across time. Several cancer types important in children, adolescents, and young adults were not historically estimated by either study, and a comprehensive synthesis of global cancer burden across previous decades, with forecasts of future burden, has not previously been published. The GBD 2023 framework provides global, regional, national, and select subnational burden estimates from 1990 to 2023 for 375 diseases and injuries, including 55 cancer types and groupings (47 of which are reported in this Article), nine of which were newly estimated in GBD 2021.<sup>23–26</sup> Risk-attributable cancer burden was estimated for behavioural, environmental and occupational, and metabolic risk factors from 1990 to 2023, and forecasts of cancer burden were estimated up to 2050.<sup>23,27</sup> This manuscript was produced as part of the GBD Collaborator Network and in accordance with the GBD Protocol.<sup>28</sup>

## Methods

### Overview

GBD offers a framework for quantifying the global burden of disease across diseases, injuries, and risk factors using comprehensive and comparable measures of burden. GBD estimates are provided by location, age, sex, and across time, and are updated regularly to provide estimates reflecting newly available data and methodological improvements. Findings from GBD 2023—the current GBD round—supersede those from GBD 2021 and all previous GBD rounds. Our analysis does not reflect the potential impact of the COVID-19 pandemic on cancer burden as these data were too scarce to be applied comprehensively across locations and measures at the time of the analysis. Details on data sources and code for this GBD 2023 analysis are available on the IHME website. This study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (appendix 1 pp 4–5).<sup>29</sup> The GBD used de-identified data, and the waiver of informed consent was reviewed and approved

by the University of Washington Institutional Review Board (study number 9060).

### Presentation of results

Cancers are defined as C00-C97 in the International Classification of Diseases 10th revision (ICD-10).<sup>30</sup> Non-melanoma skin cancer estimates are included in one summary result reporting total cancer incidence and deaths globally, and are otherwise excluded from cancer aggregates for consistency across results. Details on specific ICD-10 codes included in the modelling of each GBD cancer cause are defined in appendix 1 (pp 12–21). GBD 2023 also provides estimates for an additional eight neoplasm types and groupings, which are not included in this report but are available online in the GBD Results Tool and GBD Compare visualisation; these include other neoplasms such as myelodysplastic, myeloproliferative, and other hemopoietic neoplasms; and other benign and in situ neoplasms. Detailed results for non-melanoma skin cancers are also available in the online GBD tools (eg, GBD Results Tool and GBD Compare visualisation). Results in this analysis are presented globally and nationally and for four groups of countries based on World Bank income group FY25 classifications (ie, low, lower-middle, upper-middle, and high) for 2023.<sup>31</sup> As not all GBD locations are included in the World Bank classifications, these estimates might not sum to the global estimate. All point estimates are accompanied by 95% uncertainty intervals (UIs). Rates are reported per 100 000 population, and the GBD 2023 world standard population was used for presentation of age-standardised rates (appendix 1 p 82).

### Cancer fatal and non-fatal burden estimation, 1990–2023

GBD 2023 estimates of the fatal and non-fatal burden of cancer were modelled using 4499 site-years from population-based cancer registries (144 new for GBD 2023 compared with GBD 2021), 19 485 site-years from vital registration systems (2097 new), and 421 site-years from verbal autopsy reports (99 new; appendix 1 pp 22–23; for maps of the number of site-years of available cancer data for each data source type see appendix 2 pp 1–4). Cancer mortality estimates were made using Cause of Death Ensemble models (CODEm),<sup>32</sup> based on vital registration and verbal autopsy mortality data, as well as cancer registry incidence data that were converted to mortality estimates using mortality-to-incidence ratios (MIRs). New for GBD 2023, cancer registry data were adjusted to align with vital registration data to account for systematic differences, and excluded from CODEm models where directly overlapping (appendix 1 p 59). CODEm is a GBD modelling tool that uses all available data to build an ensemble of different statistical models and covariate combinations, to produce cause-specific mortality estimates for each age group, sex, location, and year, with model performance

For the GBD Results Tool see <https://vizhub.healthdata.org/gbd-results/>

For the GBD Compare visualisation see <https://vizhub.healthdata.org/gbd-compare>

See Online for appendix 2

For more on the GBD 2023 data sources and code see <https://ghdx.healthdata.org/gbd-2023>

See Online for appendix 1

evaluated using out-of-sample predictive validity tests (appendix 1 pp 59–74).<sup>24</sup> Transforming cancer registry incidence data to mortality estimates increased data availability for mortality modelling, especially in locations where mortality data were scarce. MIRs were estimated for each cancer type using either a spatiotemporal Gaussian process regression model that used matching incidence and mortality data from population-based cancer registries or,<sup>23,24</sup> if these data sources were too sparse for a particular cancer type, a negative binomial model (appendix 1 pp 56–58). The cancer-specific mortality estimates produced with CODEm, together with estimates for all other causes in GBD, were then scaled to all-cause mortality estimates, which were modelled independently, to produce final estimates of cancer mortality.<sup>33</sup> YLLs were estimated as the product of the number of cancer-specific deaths for each age group and the standard life expectancy at that age. For full details on estimating the fatal cancer burden for GBD 2023 see appendix 1 (p 59) and the GBD 2023 Causes of Death Collaborators publication.<sup>24</sup>

Non-fatal cancer-specific estimates were produced by first dividing final cancer mortality estimates by their corresponding MIRs to produce incidence estimates. 10-year cancer prevalence estimates were then produced using the incidence estimates from the previous step, expected background mortality, and survival estimates modelled from MIRs (appendix 1 p 77). Next, these prevalence estimates were split into phases of cancer care to estimate YLDs. Cancer care phases differed depending on whether cohorts were estimated to survive 10 years after cancer diagnosis. For surviving cohorts, the phases were: (1) diagnosis and treatment and (2) remission. For the non-surviving cohorts, the phases were: (1) diagnosis and treatment, (2) remission, (3) metastatic or disseminated, and (4) terminal. For five cancers (ie, bladder cancer, breast cancer, colon and rectum cancer, larynx cancer, and prostate cancer), an additional phase beyond 10 years represented ongoing disability from surgical procedures related to cancer treatment. YLD estimates were calculated as the product of the prevalence of each cancer phase and a phase-specific disability weight (appendix 1 pp 78–81). Disability weights quantify the magnitude of health loss associated with a particular health outcome, and range from zero, equating to full health, to one, equating to death (appendix 1 p 81). Finally, DALYs were calculated as the sum of YLDs and YLLs. For full details on estimating the non-fatal cancer burden for GBD 2023 see appendix 1 (p 76) and the GBD 2023 Disease and Injury and Risk Factor Collaborators publication.<sup>23</sup>

#### Sustainable Development Goal progress

Progress towards achievement of UN SDG target 3.4, which aims to “reduce by one-third premature mortality from NCDs” was estimated specific to cancer.<sup>13</sup> The probability of dying due to cancer between the ages of

30 and 70 years was estimated by transforming total cancer (without non-melanoma skin cancer) mortality rates for each age group between 30 and 70 years into probabilities, then summing the probabilities across age groups (appendix 1 pp 82–83).

#### Cancer risk-attributable burden, 1990–2023

GBD 2023 also estimated risk-attributable burden for 44 risk factors associated with 35 cancer types (appendix 2 pp 10–12).<sup>23</sup> These risk factors are potentially modifiable and categorised into three main categories: occupational and environmental risk factors, metabolic risk factors, and behavioural risk factors, with more detailed categories presented in hierarchical levels. Risk factors and associated cancer pairs were identified for possible inclusion in the analysis based on (1) importance of the risk factor to disease burden or policy, (2) sufficient data and methods to estimate exposure across locations, and (3) evidence that the effects of exposure on the outcome can be generalised across populations. Next, data for risk–outcome associations were identified and extracted through systematic reviews in accordance with the PRISMA framework.<sup>34</sup> Relative risks for the majority of risk factor–cancer pairs were estimated by synthesising all available relative risk data and estimates of exposure levels, distribution of exposure, and the theoretical minimum risk exposure level (TMREL; the level of exposure that would minimise health risk) using an ensemble spline modelling tool called meta-regression–Bayesian, regularised, trimmed (MR-BRT).<sup>23,35</sup> MR-BRT captures the shape of relative risk functions (including if the function is non-linear), incorporates different exposure ranges, tests and adjusts for systematic biases, and trims outliers. Select risk factor–cancer pairs were estimated using alternative methods, such as the unsafe sex–cervical cancer pairing, in which a direct population attributable fraction strategy was used; more details on methods for estimating each risk factor–cancer pair can be found in the GBD 2023 Disease and Injury and Risk Factors Collaborators publication.<sup>23</sup> The GBD 2023 comparative risk assessment framework was then used to estimate the proportion of cancer burden attributable to each risk factor, for each relevant cancer type.<sup>23</sup> Population attributable fraction is an estimate of the proportional reduction in the risk of cancer that would occur if exposure to a particular risk factor were reduced to the TMREL.

#### Forecasting cancer burden, 2024–50

The Institute for Health Metrics and Evaluation forecasting framework was used to forecast cause-specific cancer burden from 2024 to 2050, with reference scenario results presented. In brief, forecasted independent drivers of health, such as age-specific fertility rates by location, age-specific educational attainment by location, and risk factor exposure (measured as summary exposure value) by

location, age, and sex are used to forecast cause-specific fatal disease outcomes (deaths and YLLs) by age, sex, and location. A three-component model was used to forecast cancer cause-specific mortality separately for males and females. The model included: (1) risk-deleted (underlying) mortality modelled as a function of Socio-demographic Index (SDI) and time; (2) a risk factor scalar that captures the cause-specific effect of all risk factors that are deemed causal by the GBD comparative risk assessment for the cancer cause in question; and (3) an autoregressive integrated moving average (ARIMA) model to capture unexplained residual mortality. The all-cause forecasts constrained the cause-specific forecasts at successively deeper levels of the GBD cause hierarchy using cascading mortality models and thus ensured a robust estimate of cause-specific mortality. For cancers without risk factors associated in GBD 2023, the second component of the model was not performed. The future incidence of cancers was forecasted by dividing forecasted mortality estimates by forecasted MIRs computed using a mixed-effects regression model with SDI as a covariate. Prevalence was computed from incidence using a forecasted prevalence-to-incidence ratio, and YLDs from forecasted prevalence using average disability weights for each cause from the GBD. More details on the forecasting framework are described in the GBD 2021 forecasting capstone publication and appendices.<sup>27</sup>

To ensure forecasted values align with GBD 2023 past estimates, the GBD 2021 forecasts were shifted to the GBD 2023 estimate for the year 2023, maintaining the relative change in values over time. The mean-level ratio of the 2023 value estimated in GBD 2023 to the 2023 value forecasted in GBD 2021 was applied to each of the GBD 2021 forecasted years between 2024 and 2050 at the mean level. A similar multiplier was computed for both the upper and lower boundaries (95% UIs) as well, by computing the ratio of the distance between the mean and boundary for 2023 in GBD 2023 estimates and 2023 in GBD 2021 forecasted estimates. This scalar was applied to the distance between the mean and boundaries for each forecasted year between 2024 and 2050.

### Uncertainty estimation

At each modelling step described above, parameter uncertainty was incorporated by randomly drawing 250 samples from parameter distributions and propagating this uncertainty forward through each subsequent step of the analysis. Final estimates calculated the 2.5th and 97.5th percentile values of the posterior distribution as the 95% UI.

### Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report.

## Results

### Cancer burden in 2023

There were 18.5 million (95% UI 16.4–20.7) new cancer cases (25.7 million [23.4–28.1] when including non-melanoma skin cancers) and 10.4 million (9.65–10.9) cancer deaths (10.4 million [9.71–11.0] when including non-melanoma skin cancers) estimated to occur globally in 2023 (GBD Results Tool; table 1). Premature mortality comprised the majority of the 271 million (255–285) global cancer DALYs in 2023 (table 1), with 97.0% (95.9–97.8; 263 million [247–277]) of DALYs due to YLLs and 3.0% (2.2–4.1; 8.27 million [5.95–11.4]) due to YLDs (appendix 2 p 24). Globally in 2023, there were 9.56 million (8.51–10.7) new cancer cases in males and 8.99 million (7.85–10.2) in females; 5.77 million (5.37–6.12) cancer deaths in males and 4.61 million (4.17–5.00) cancer deaths in females (appendix 2 pp 13–14). The male-to-female ratio for cancer cases was 1.07 (1.00–1.14) and for cancer deaths 1.25 (1.14–1.36; appendix 2 pp 15–16).

The cancer types contributing the greatest global burden in terms of incident cases for males and females combined in 2023 were breast cancer (2.30 million [95% UI 2.03–2.61]), tracheal, bronchus, and lung cancer (2.30 million [2.08–2.53]), colon and rectum cancer (2.29 million [2.01–2.55]), prostate cancer (1.41 million [1.19–1.63]), and stomach cancer (1.26 million [1.07–1.52]). The greatest contributors to global cancer deaths for males and females combined in 2023 were tracheal, bronchus, and lung cancer (2.04 million [1.84–2.21] deaths), colon and rectum cancer (1.11 million [1.00–1.20]), stomach cancer (935 000 [797 000–1 060 000]), breast cancer (778 000 [683 000–870 000]), and oesophageal cancer (577 000 [510 000–649 000]; table 2).

The distribution of cancer across World Bank income groups in 2023 differed for age-standardised incidence and mortality rates. In 2023, the age-standardised cancer incidence rate was highest in the high-income group (303.2 [95% UI 262.9–344.1]) and lowest in the lower-middle-income group (125.7 [112.5–139.7]). Similarly, the highest age-standardised death rate was in the high-income group (124.1 [114.5–129.2]), while the lowest was the lower-middle-income group (94.2 [86.4–103.0]; table 1).

The cancer type with the highest burden in any given country in 2023 differed by sex. In males, prostate cancer was the most common incident cancer in 112 countries and territories, followed by tracheal, bronchus, and lung cancer (53 countries) and colon and rectum cancer (17 countries; appendix 2 p 5). In females, breast cancer was the most common incident cancer in 164 countries and territories, followed by cervical cancer (37 countries; appendix 2 p 6). For deaths, tracheal, bronchus, and lung cancer was the leading cause of cancer death in males in 111 countries and territories, followed by prostate cancer (57 countries) and stomach cancer (14 countries; appendix 2 p 7). In females, breast cancer was the most

	Global	High-income countries	Upper-middle-income countries	Lower middle-income countries	Low-income countries
<b>Incidence</b>					
Cases in 2023, in thousands (95% UI)	18 500 (16 400 to 20 700)	7780 (6700 to 8760)	6860 (6070 to 7760)	3190 (2850 to 3580)	698 (613 to 797)
Cases, percentage change 1990–2023 (95% UI)	105.1 (79.5 to 137.4)	67.7 (42.9 to 96.2)	117.3 (88.0 to 159.0)	219.5 (170.8 to 277.2)	194.4 (142.8 to 252.9)
Age-standardised incidence rate 2023, per 100 000 (95% UI)	205.1 (180.9 to 229.1)	303.2 (262.9 to 344.1)	182.7 (160.5 to 207.8)	125.7 (112.5 to 139.7)	166.9 (147.4 to 188.5)
Age-standardised incidence rate, percentage change 1990–2023 (95% UI)	-7.1 (-18.4 to 7.4)	-3.4 (-17.9 to 14.8)	-8.8 (-20.9 to 8.9)	28.6 (10.0 to 51.2)	23.6 (3.1 to 43.8)
<b>Mortality</b>					
Deaths in 2023, in thousands (95% UI)	10 400 (9650 to 10 900)	3530 (3210 to 3700)	4130 (3800 to 4440)	2240 (2060 to 2460)	455 (406 to 505)
Deaths, percentage change 1990–2023 (95% UI)	74.3 (62.2 to 86.2)	37.7 (30.2 to 42.3)	68.7 (48.7 to 87.9)	195.6 (163.7 to 234.7)	171.0 (136.8 to 209.7)
Age-standardised mortality rate 2023, per 100 000 (95% UI)	114.6 (106.5 to 121.0)	124.1 (114.5 to 129.2)	109.3 (100.7 to 117.4)	94.2 (86.4 to 103.0)	121.3 (106.1 to 134.7)
Age-standardised mortality rate, percentage change 1990–2023 (95% UI)	-23.9 (-29.1 to -19.1)	-27.3 (-30.1 to -25.5)	-33.5 (-41.4 to -25.7)	16.6 (3.9 to 32.8)	14.2 (-0.3 to 31.1)
<b>DALYs</b>					
DALYs in 2023, in millions (95% UI)	271 000 (255 000 to 285 000)	74 000 (69 200 to 77 000)	108 000 (100 000 to 116 000)	71 900 (66 100 to 78 200)	17 400 (15 800 to 19 400)
DALYs, percentage change 1990–2023 (95% UI)	53.4 (42.6 to 64.5)	14.7 (10.2 to 17.8)	39.2 (24.2 to 54.0)	159.2 (129.8 to 193.3)	147.8 (115.9 to 183.3)
Age-standardised DALY rate 2023, per 100 000 (95% UI)	3023.1 (2840.3 to 3177.3)	2969.7 (2806.5 to 3071.0)	2890.4 (2691.4 to 3107.3)	2727.6 (2510.9 to 2965.9)	3791.6 (3385.4 to 4200.8)
Age-standardised DALY rate, percentage change 1990–2023 (95% UI)	-26.1 (-31.1 to -20.9)	-33.0 (-35.0 to -31.5)	-37.4 (-44.1 to -30.4)	12.7 (0.3 to 27.0)	9.8 (-4.7 to 25.4)

DALYs=disability-adjusted life-years. UI=uncertainty interval.

**Table 1: Cancer incidence, death, and DALY counts and age-standardised rates in 2023 and percentage change in counts and age-standardised rates between 1990 and 2023 by World Bank income group for all ages and sexes combined**

common cause of cancer death in 134 countries and territories, followed by tracheal, bronchus, and lung cancer (29 countries) and cervical cancer (27 countries; appendix 2 p 8).

Globally in 2023, cancer incidence rates increased with age until the age group of 95 years and older, while mortality rates continually increased with age (figure 1). Childhood cancers occurring in the 0–14 year age range comprised 1.4% (95% UI 1.2–1.8) of all cancer cases and 1.0% (0.9–1.1) of all cancer deaths globally in 2023, but 3.2% (2.9–3.6) of all cancer DALYs (appendix 2 p 17). The most common cancer types occurring and causing death in children (age 0–14 years) were acute lymphoid leukaemia and brain and CNS cancers, whereas carcinomas tended to be more common in the adolescent and young adult (age 15–39 years) cancer age range. Breast cancer and cervical cancer contributed the greatest share to both incidence and mortality, even for males and females combined, highlighting a disproportionate burden of adolescent and young adult cancers on females (figure 1). Adolescent and young adult cancers contributed to 7.7% (7.0–8.5) of all cancer cases, 4.6% (4.3–5.1) of all cancer deaths, and 10.6% (10.0–11.4) of all cancer DALYs globally in 2023, and in total 9.1% (8.2–10.1) of cancers globally in 2023

occurred in individuals younger than 40 years (appendix 2 p 17).

Breast cancer was also the largest contributor to cancer incidence in adults aged 40–64 years globally in 2023, followed by colon and rectum cancer and tracheal, bronchus, and lung cancer. For mortality in this age range, tracheal, bronchus, and lung cancer was the largest contributor, followed by breast, colon and rectum, and stomach (figure 1). Cancers in this age group contributed to 38.2% (95% UI 37.1–39.9) of all cancer cases, 32.7% (31.2–34.5) of all cancer deaths, and 45.2% (43.9–46.9) of all cancer DALYs globally in 2023. In contrast, cancers in older adults aged 65 years and older contributed to 52.7% (50.5–54.3) of all cancer cases, 61.7% (59.5–63.4) of all cancer deaths, and 40.9% (39.1–42.5) of all cancer DALYs globally in 2023, with tracheal, bronchus, and lung cancer and colon and rectum cancer the largest contributors to both incidence and mortality (appendix 2 pp 2, 17).

#### Risk-attributable cancer burden in 1990–2023

Overall, 41.7% (95% UI 37.8–45.4) of cancer deaths globally in 2023 were attributable to potentially modifiable risk factors modelled in GBD 2023

	Incident cases, 2023, in thousands (95% UI)	Incident cases, percentage change 1990 to 2023 (95% UI)	Age-standardised incidence rate, 2023 (95% UI)	Age-standardised incidence rate, percentage change 1990 to 2023 (95% UI)	Deaths, 2023, in thousands (95% UI)	Deaths, percentage change 1990 to 2023 (95% UI)	Age-standardised death rate, 2023 (95% UI)	Age-standardised death rate, percentage change 1990 to 2023 (95% UI)	DALYs, 2023, in thousands (95% UI)	DALYs, percentage change 1990 to 2023 (95% UI)	Age-standardised DALY rate, 2023 (95% UI)	Age-standardised DALY rate, percentage change 1990 to 2023 (95% UI)
Total cancers excluding non-melanoma skin cancer	18 500 (16 400 to 20 700)	105.1 (79.5 to 137.4)	205.1 (180.9 to 229.1)	-7.1 (-18.4 to 7.4)	10 400 (9650 to 10 900)	74.3 (62.2 to 86.2)	114.6 (106.5 to 121.0)	-23.9 (-29.1 to -19.1)	271 000 (255 000 to 285 000)	53.4 (42.6 to 64.5)	3023.1 (2840.3 to 3177.3)	-26.1 (-31.1 to -20.9)
Lip and oral cavity cancer	422 (361 to 498)	145.5 (98.9 to 209.2)	4.6 (4.0 to 5.5)	11.2 (-9.8 to 39.7)	229 (197 to 267)	133.9 (89.0 to 185.4)	2.5 (2.2 to 2.9)	3.0 (-16.3 to 25.6)	6540 (5600 to 7680)	120.1 (76.4 to 170.9)	72.2 (61.7 to 84.7)	3.8 (-16.5 to 27.6)
Nasopharynx cancer	167 (130 to 218)	86.3 (34.9 to 167.9)	1.9 (1.5 to 2.4)	-7.5 (-33.4 to 32.9)	76 (63.5 to 87.9)	20.9 (-7.7 to 52.5)	0.8 (0.7 to 1.0)	-42.3 (-56.0 to -27.7)	2600 (2150 to 3050)	12.8 (-15.2 to 42.7)	29.2 (24.0 to 34.2)	-42.2 (-56.6 to -26.9)
Other pharynx cancer	191 (159 to 227)	189.2 (136.8 to 263.1)	2.1 (1.7 to 2.5)	31.0 (7.1 to 64.7)	117 (93.8 to 144)	166.2 (112.5 to 242.0)	1.3 (1.0 to 1.6)	18.9 (-4.9 to 52.3)	3420 (2680 to 4240)	151.6 (99.5 to 226.7)	37.3 (29.2 to 46.4)	17.2 (-7.2 to 51.6)
Oesophageal cancer	605 (539 to 668)	53.1 (30.9 to 82.6)	6.6 (5.9 to 7.3)	-32.8 (-42.4 to -20.4)	577 (510 to 649)	51.2 (28.1 to 79.2)	6.3 (5.6 to 7.1)	-34.6 (-44.2 to -22.4)	14 100 (12 600 to 15 800)	37.0 (16.6 to 65.2)	152.9 (136.4 to 171.7)	-38.3 (-47.4 to -25.8)
Stomach cancer	1260 (1070 to 1520)	20.0 (2.0 to 41.5)	13.8 (11.7 to 16.6)	-47.5 (-55.3 to -38.4)	935 (797 to 1060)	2.4 (-12.6 to 20.3)	10.3 (8.7 to 11.7)	-56.0 (-62.4 to -48.6)	22 500 (19 300 to 26 000)	-8.8 (-22.5 to 7.3)	246.7 (211.9 to 285.5)	-58.4 (-64.5 to -51.3)
Colon and rectum cancer	2290 (2010 to 2550)	142.7 (113.0 to 177.4)	25.1 (22.0 to 28.0)	2.1 (-10.3 to 16.2)	1110 (1000 to 1200)	90.2 (74.4 to 106.0)	12.2 (11.1 to 13.3)	-22.0 (-27.8 to -15.9)	26 200 (24 000 to 28 500)	76.3 (60.4 to 93.4)	287.4 (263.3 to 313.0)	-21.2 (-28.1 to -14.0)
Liver cancer	570 (500 to 639)	109.9 (78.4 to 144.6)	6.3 (5.5 to 7.0)	-3.4 (-17.5 to 12.3)	508 (451 to 571)	104.4 (75.4 to 138.9)	5.6 (4.9 to 6.3)	-7.6 (-20.7 to 7.6)	13 900 (12 200 to 16 100)	76.5 (48.3 to 112.0)	154.8 (135.0 to 179.6)	-13.9 (-27.7 to 3.4)
Liver cancer due to hepatitis B, Level 4	216 (188 to 249)	75.3 (44.5 to 108.8)	2.4 (2.1 to 2.7)	-16.3 (-30.7 to -0.1)	189 (162 to 221)	69.6 (41.3 to 102.9)	2.1 (1.8 to 2.4)	-20.2 (-33.4 to -4.2)	6020 (5140 to 7140)	54.2 (27.2 to 88.6)	66.9 (57.1 to 79.5)	-23.3 (-36.4 to -6.2)
Liver cancer due to hepatitis C, Level 4	169 (141 to 202)	136.8 (101.9 to 175.1)	1.9 (1.6 to 2.2)	1.6 (-13.1 to 16.9)	155 (131 to 188)	130.7 (97.8 to 168.5)	1.7 (1.4 to 2.1)	-2.8 (-16.6 to 12.5)	3390 (2810 to 4160)	101.2 (69.6 to 136.7)	37.0 (30.8 to 45.4)	-10.9 (-24.6 to 4.2)
Liver cancer due to alcohol use, Level 4	107 (85.9 to 133)	159.2 (118.2 to 202.1)	1.2 (0.9 to 1.4)	14.1 (-4.0 to 32.7)	95.2 (76.4 to 118)	150.2 (112.7 to 192.9)	1.0 (0.8 to 1.3)	8.9 (-7.1 to 26.8)	2440 (1930 to 3080)	132.1 (95.1 to 175.5)	26.5 (20.9 to 33.4)	5.5 (-11.3 to 25.2)
Liver cancer due to non-alcoholic steatohepatitis, Level 4	44.9 (34.4 to 56)	183.8 (138.2 to 238.2)	0.5 (0.4 to 0.6)	26.5 (6.2 to 50.5)	41.7 (31.2 to 52.7)	179.2 (137.1 to 233.4)	0.5 (0.3 to 0.6)	21.9 (3.7 to 45.6)	1060 (810 to 1350)	147.9 (107.0 to 201.9)	11.6 (8.9 to 14.9)	16.5 (-2.1 to 42.1)
Hepatoblastoma, Level 4	5.78 (4.33 to 7.93)	-2.2 (-31.9 to 47.7)	0.1 (0.1 to 0.1)	-8.8 (-36.7 to 38.2)	3.53 (2.28 to 5.22)	-21.5 (-50.2 to 27.6)	0.1 (0.0 to 0.1)	-25.7 (-53.0 to 21.1)	310 (200 to 460)	-21.2 (-50.0 to 27.7)	4.8 (3.1 to 7.1)	-25.3 (-52.7 to 21.5)
Liver cancer due to other causes, Level 4	27.3 (21 to 33.8)	95.9 (61.7 to 132.2)	0.3 (0.2 to 0.4)	-6.5 (-21.9 to 11.3)	23.6 (18.3 to 29.5)	89.6 (62.2 to 123.2)	0.3 (0.2 to 0.3)	-11.5 (-23.4 to 4.5)	711 (554 to 886)	65.3 (38.8 to 101.8)	8.0 (6.2 to 9.9)	-16.3 (-29.6 to 1.9)
Gallbladder and biliary tract cancer	227 (197 to 263)	103.4 (82.3 to 128.3)	2.5 (2.2 to 2.9)	-15.4 (-24.1 to -5.2)	185 (161 to 218)	82.8 (63.1 to 103.2)	2.0 (1.8 to 2.4)	-25.2 (-33.2 to -17.1)	4040 (3480 to 4830)	68.7 (49.4 to 89.9)	44.0 (38.0 to 52.7)	-26.5 (-34.6 to -17.5)
Pancreatic cancer	574 (518 to 609)	152.8 (132.9 to 172.5)	6.3 (5.7 to 6.7)	6.3 (-1.4 to 14.6)	552 (504 to 587)	150.5 (133.0 to 169.6)	6.0 (5.5 to 6.4)	3.6 (-3.0 to 10.9)	12 300 (11 500 to 13 000)	125.8 (108.5 to 145.9)	133.3 (124.4 to 141.8)	-0.6 (-7.9 to 7.9)
Larynx cancer	234 (197 to 281)	82.8 (44.8 to 121.9)	2.5 (2.1 to 3.0)	-19.2 (-35.7 to -2.1)	132 (113 to 159)	63.1 (33.6 to 94.9)	1.4 (1.2 to 1.7)	-29.1 (-41.8 to -15.2)	3610 (3000 to 4400)	54.6 (25.2 to 86.8)	39.1 (32.5 to 47.7)	-29.8 (-43.2 to -15.3)
Tracheal, bronchus, and lung cancer	2300 (2080 to 2530)	96.0 (77.8 to 117.1)	24.9 (22.5 to 27.4)	-15.0 (-22.8 to -5.9)	2040 (1840 to 2210)	85.8 (68.6 to 100.6)	22.2 (19.9 to 24.1)	-20.3 (-27.7 to -14.1)	46 700 (42 200 to 50 900)	62.0 (47.6 to 75.1)	504.9 (455.7 to 550.0)	-27.5 (-34.0 to -21.6)

(Table 2 continues on next page)

	Incident cases, 2023, in thousands (95% UI)	Incident cases, percentage change 1990 to 2023 (95% UI)	Age-standardised incidence rate, 2023 (95% UI)	Age-standardised incidence rate, percentage change 1990 to 2023 (95% UI)	Deaths, 2023, in thousands (95% UI)	Deaths, percentage change 1990 to 2023 (95% UI)	Age-standardised death rate, 2023 (95% UI)	Age-standardised death rate, percentage change 1990 to 2023 (95% UI)	DALYs, in thousands (95% UI)	DALYs, percentage change 1990 to 2023 (95% UI)	Age-standardised DALY rate, 2023 (95% UI)	Age-standardised DALY rate, percentage change 1990 to 2023 (95% UI)
(Continued from previous page)												
Malignant skin melanoma	322 (253 to 397)	150.1 (86.8 to 236.8)	3.6 (2.8 to 4.4)	17.5 (-11.9 to 57.1)	66.2 (59.6 to 75.2)	104.5 (88.0 to 118.6)	0.7 (0.7 to 0.8)	-10.3 (-17.6 to -3.9)	1810 (1590 to 2120)	74.6 (56.1 to 89.1)	20.3 (17.7 to 23.8)	-15.4 (-24.3 to -8.0)
Soft tissue and other extraosseous sarcomas	137 (107 to 171)	111.6 (51.3 to 185.1)	1.6 (1.2 to 2.0)	11.0 (-19.5 to 47.3)	60.8 (49 to 75.7)	89.1 (33.7 to 142.8)	0.7 (0.6 to 0.9)	-4.5 (-31.2 to 21.9)	2210 (1720 to 2880)	57.8 (5.0 to 110.2)	26.6 (20.4 to 34.9)	-5.1 (-35.6 to 26.2)
Malignant neoplasm of bone and articular cartilage	109 (81.4 to 157)	86.4 (23.5 to 196.2)	1.3 (1.0 to 1.9)	8.7 (-27.9 to 72.9)	76.3 (59.9 to 96.3)	88.1 (41.7 to 147.7)	0.9 (0.7 to 1.1)	-0.8 (-24.1 to 29.2)	2990 (2260 to 3890)	58.3 (13.1 to 114.4)	35.9 (26.8 to 47.0)	-1.3 (-29.0 to 33.2)
Breast cancer	2300 (2030 to 2610)	146.0 (111.0 to 187.8)	25.5 (22.4 to 29.0)	12.8 (-3.3 to 32.0)	778 (683 to 870)	111.1 (85.4 to 139.2)	8.7 (7.6 to 9.7)	-7.8 (-18.7 to 4.5)	24 500 (21 500 to 27 800)	107.7 (77.7 to 139.9)	274.4 (239.7 to 311.4)	-1.0 (-14.8 to 14.5)
Cervical cancer	867 (676 to 1140)	86.2 (40.3 to 152.6)	9.9 (7.7 to 13.0)	-4.4 (-27.7 to 29.0)	368 (290 to 476)	70.9 (32.3 to 133.0)	4.1 (3.2 to 5.3)	-19.6 (-37.7 to 8.8)	13 200 (10 200 to 17 300)	70.1 (29.1 to 136.0)	149.7 (114.8 to 197.1)	-13.3 (-34.2 to 19.8)
Uterine cancer	519 (440 to 617)	157.8 (107.2 to 223.6)	5.6 (4.8 to 6.7)	14.6 (-7.4 to 43.4)	108 (93 to 126)	85.4 (56.5 to 117.4)	1.2 (1.0 to 1.4)	-21.9 (-33.9 to -9.1)	2900 (2450 to 3370)	76.8 (44.6 to 113.0)	31.6 (26.7 to 36.8)	-20.0 (-34.4 to -4.1)
Ovarian cancer	331 (284 to 394)	109.2 (74.6 to 146.0)	3.7 (3.1 to 4.4)	-2.1 (-17.8 to 15.1)	221 (190 to 254)	108.1 (77.4 to 141.0)	2.4 (2.1 to 2.8)	-9.3 (-22.4 to 4.7)	6480 (5450 to 7650)	104.9 (67.5 to 142.9)	72.0 (60.4 to 85.0)	-2.9 (-20.5 to 15.1)
Prostate cancer	1410 (1190 to 1630)	168.7 (117.1 to 239.2)	15.2 (12.9 to 17.6)	8.8 (-11.7 to 36.6)	469 (413 to 526)	118.2 (95.9 to 148.3)	5.2 (4.6 to 5.9)	-17.2 (-25.6 to -6.1)	8850 (7790 to 9960)	108.1 (84.9 to 137.8)	96.7 (84.9 to 108.7)	-16.2 (-25.4 to -4.5)
Testicular cancer	97.6 (73.4 to 128)	122.5 (50.9 to 225.8)	1.2 (0.9 to 1.5)	40.4 (-4.6 to 104.9)	11.8 (9.56 to 14.5)	54.1 (11.5 to 94.6)	0.1 (0.1 to 0.2)	-12.1 (-36.1 to 10.9)	584 (469 to 730)	48.0 (5.8 to 91.1)	7.1 (5.7 to 8.9)	-6.3 (-32.9 to 20.7)
Kidney cancer	397 (346 to 460)	132.8 (97.7 to 173.9)	4.4 (3.8 to 5.1)	8.3 (-7.4 to 26.7)	165 (147 to 180)	106.1 (90.5 to 122.2)	1.8 (1.6 to 2.0)	-11.0 (-17.9 to -4.5)	4050 (3590 to 4500)	73.7 (58.2 to 88.6)	45.4 (40.1 to 50.3)	-16.4 (-23.8 to -8.7)
Bladder cancer	569 (499 to 643)	105.5 (75.5 to 143.7)	6.2 (5.5 to 7.1)	-13.9 (-26.1 to 1.4)	234 (209 to 258)	91.5 (74.1 to 112.0)	2.6 (2.3 to 2.9)	-24.0 (-30.3 to -16.2)	4630 (4210 to 5140)	68.6 (53.7 to 89.9)	50.7 (46.2 to 56.3)	-28.2 (-34.3 to -19.1)
Brain and central nervous system cancer	377 (315 to 466)	86.4 (50.8 to 131.6)	4.3 (3.6 to 5.4)	0.9 (-18.1 to 25.2)	263 (230 to 311)	82.9 (61.9 to 100.1)	3.0 (2.6 to 3.5)	-6.4 (-16.8 to 1.9)	9110 (7920 to 10900)	41.7 (23.5 to 57.9)	107.4 (93.1 to 128.5)	-16.1 (-26.7 to -7.4)
Eye cancer	20.9 (15.4 to 29.4)	34.4 (-8.4 to 102.3)	0.3 (0.2 to 0.4)	-19.8 (-42.0 to 15.5)	10.1 (7.22 to 14.2)	8.3 (-46.1 to 88.5)	0.1 (0.1 to 0.2)	-34.5 (-65.2 to 13.2)	489 (294 to 810)	-12.7 (-65.5 to 102.8)	6.7 (3.7 to 11.7)	-33.8 (-73.9 to 53.9)
Retinoblastoma, Level 4	5.4 (3.02 to 9.58)	-2.9 (-65.7 to 184.0)	0.1 (0.0 to 0.1)	-9.6 (-68.1 to 164.2)	3.25 (1.28 to 7.1)	-31.6 (-80.6 to 155.9)	0.0 (0.0 to 0.1)	-36.3 (-82.0 to 138.5)	285 (113 to 622)	-31.2 (-80.5 to 156.8)	4.4 (1.7 to 9.5)	-35.9 (-81.8 to 139.6)
Other eye cancers, Level 4	15.5 (11.5 to 22.6)	55.2 (3.2 to 144.6)	0.2 (0.1 to 0.3)	-23.8 (-49.0 to 19.4)	6.81 (5.39 to 8.81)	50.1 (21.5 to 79.6)	0.1 (0.1 to 0.1)	-33.3 (-45.4 to -21.0)	204 (156 to 279)	40.1 (9.9 to 68.0)	2.3 (1.8 to 3.2)	-29.5 (-45.0 to -15.9)
Neuroblastoma and other peripheral nervous cell tumours	20.9 (13.9 to 30.1)	67.9 (0.2 to 202.3)	0.3 (0.2 to 0.4)	33.5 (-21.5 to 137.4)	5.99 (5.01 to 7.6)	68.8 (33.0 to 111.1)	0.1 (0.1 to 0.1)	13.0 (-10.9 to 41.8)	332 (266 to 441)	35.2 (2.8 to 75.1)	4.5 (3.6 to 6.1)	6.2 (-19.6 to 36.6)
Thyroid cancer	297 (220 to 373)	191.4 (104.9 to 327.0)	3.4 (2.5 to 4.2)	46.5 (3.4 to 114.0)	52.5 (44.8 to 61.1)	120.6 (84.5 to 170.1)	0.6 (0.5 to 0.7)	-3.8 (-19.6 to 18.2)	1560 (1310 to 1880)	112.1 (73.1 to 167.9)	17.6 (14.8 to 21.3)	4.4 (-14.9 to 31.5)
Mesothelioma	29.2 (25.7 to 32.2)	99.3 (71.9 to 126.8)	0.3 (0.3 to 0.4)	-14.2 (-26.0 to -2.6)	27.9 (24.6 to 30.8)	105.4 (79.6 to 132.9)	0.3 (0.3 to 0.3)	-13.0 (-23.6 to -1.6)	623 (550 to 691)	80.9 (56.5 to 109.6)	6.9 (6.0 to 7.6)	-18.3 (-29.5 to -5.3)

(Table 2 continues on next page)


	Incident cases, 2023, in thousands (95% UI)	Incident cases, percentage change 1990 to 2023 (95% UI)	Age-standardised incidence rate, 2023 (95% UI)	Age-standardised incidence rate, percentage change 1990 to 2023 (95% UI)	Deaths, 2023, in thousands (95% UI)	Deaths, percentage change 1990 to 2023 (95% UI)	Age-standardised death rate, 2023 (95% UI)	Age-standardised death rate, percentage change 1990 to 2023 (95% UI)	DALYs, 2023, in thousands (95% UI)	DALYs, percentage change 1990 to 2023 (95% UI)	Age-standardised DALY rate, 2023 (95% UI)	Age-standardised DALY rate, percentage change 1990 to 2023 (95% UI)
(Continued from previous page)												
Hodgkin lymphoma	68.7 (55.8 to 84.3)	15.0 (-7.4 to 36.3)	0.8 (0.7 to 1.0)	-32.8 (-45.7 to -20.3)	27.1 (20.8 to 34.9)	-9.9 (-30.7 to 9.0)	0.3 (0.2 to 0.4)	-51.1 (-62.0 to -41.3)	1180 (866 to 1560)	-16.0 (-38.5 to 4.1)	14.3 (10.4 to 19.0)	-47.4 (-61.9 to -34.9)
Non-Hodgkin lymphoma	632 (468 to 849)	142.9 (68.8 to 256.1)	7.1 (5.3 to 9.6)	17.1 (-18.6 to 70.8)	282 (246 to 319)	90.9 (61.0 to 126.3)	3.2 (2.8 to 3.6)	-11.8 (-25.4 to 4.4)	8290 (7080 to 9590)	58.3 (29.6 to 93.0)	96.2 (81.3 to 111.9)	-14.3 (-29.7 to 3.8)
Burkitt lymphoma, Level 4	15.9 (9.67 to 26)	99.9 (6.0 to 280.5)	0.2 (0.1 to 0.3)	34.1 (-30.1 to 152.5)	6.68 (5.04 to 9.56)	57.6 (11.4 to 138.2)	0.1 (0.1 to 0.1)	2.0 (-28.5 to 53.4)	369 (260 to 566)	33.3 (-13.2 to 112.2)	4.8 (3.4 to 7.5)	-0.6 (-35.1 to 59.3)
Other non-Hodgkin lymphoma, Level 4	616 (457 to 825)	144.3 (70.2 to 256.3)	6.9 (5.1 to 9.3)	16.7 (-18.7 to 69.9)	276 (240 to 312)	91.9 (62.2 to 127.8)	3.1 (2.7 to 3.5)	-12.2 (-25.4 to 4.2)	7920 (6800 to 9160)	59.7 (31.2 to 94.8)	91.4 (77.8 to 106.4)	-14.9 (-30.0 to 3.5)
Multiple myeloma	176 (142 to 222)	188.2 (122.3 to 288.7)	1.9 (1.6 to 2.4)	21.1 (-6.4 to 62.8)	125 (112 to 138)	156.9 (130.5 to 186.7)	1.4 (1.2 to 1.5)	5.0 (-5.7 to 16.9)	2820 (2520 to 3130)	141.3 (114.2 to 174.6)	30.7 (27.5 to 34.1)	5.2 (-6.6 to 19.5)
Leukaemia	573 (447 to 736)	42.0 (6.0 to 100.7)	6.7 (5.2 to 8.7)	-22.7 (-42.7 to 8.6)	341 (307 to 384)	26.5 (10.5 to 44.7)	3.9 (3.5 to 4.4)	-33.5 (-41.4 to -24.4)	12100 (10700 to 14000)	-7.5 (-20.9 to 9.3)	147.9 (130.3 to 171.4)	-40.8 (-49.3 to -30.5)
Acute lymphoid leukaemia, Level 4	128 (91.7 to 181)	-3.2 (-30.3 to 48.9)	1.7 (1.2 to 2.4)	-29.6 (-49.6 to 9.2)	76.9 (53.7 to 98.4)	-15.5 (-32.0 to 6.6)	1.0 (0.7 to 1.2)	-42.7 (-53.7 to -27.7)	4350 (3120 to 5470)	-29.5 (-43.6 to -10.7)	57.1 (41.3 to 71.9)	-46.4 (-56.9 to -32.2)
Chronic lymphoid leukaemia, Level 4	128 (101 to 157)	88.8 (44.1 to 149.7)	1.4 (1.1 to 1.7)	-19.1 (-37.8 to 6.8)	44.9 (39.9 to 51.9)	45.2 (27.2 to 65.4)	0.5 (0.4 to 0.6)	-41.6 (-48.3 to -33.9)	985 (863 to 1190)	23.5 (4.6 to 47.9)	10.9 (9.5 to 13.1)	-44.4 (-52.5 to -34.0)
Acute myeloid leukaemia, Level 4	183 (135 to 258)	90.5 (36.9 to 178.9)	2.1 (1.5 to 3.0)	0.4 (-29.4 to 48.4)	131 (113 to 152)	71.8 (45.4 to 103.6)	1.5 (1.3 to 1.7)	-12.0 (-24.1 to 1.7)	4190 (3420 to 5190)	20.3 (-2.0 to 50.1)	49.8 (40.2 to 62.3)	-26.3 (-40.0 to -9.3)
Chronic myeloid leukaemia, Level 4	56.8 (37.7 to 80.2)	-10.6 (-43.4 to 47.7)	0.6 (0.4 to 0.9)	-56.0 (-71.9 to -27.1)	26.4 (21.1 to 32.8)	-26.7 (-43.8 to -4.1)	0.3 (0.2 to 0.4)	-65.7 (-73.1 to -55.3)	797 (600 to 1070)	-39.8 (-55.9 to -15.6)	9.3 (6.9 to 12.5)	-67.0 (-75.7 to -54.3)
Other leukaemia, Level 4	76.8 (61.7 to 96.6)	75.4 (35.2 to 128.7)	0.9 (0.7 to 1.1)	-12.0 (-31.0 to 14.3)	61.7 (49.2 to 77.3)	75.3 (37.4 to 133.1)	0.7 (0.6 to 0.9)	-16.8 (-33.7 to 9.1)	1810 (1400 to 2380)	35.1 (1.5 to 89.1)	20.8 (16.1 to 27.4)	-25.8 (-44.3 to 2.5)
Other malignant neoplasms	454 (388 to 530)	78.3 (43.7 to 122.2)	5.1 (4.4 to 6.0)	-12.0 (-28.7 to 9.3)	226 (197 to 252)	46.9 (21.4 to 72.3)	2.6 (2.2 to 2.9)	-30.6 (-42.2 to -19.3)	6690 (5730 to 7680)	14.3 (-8.1 to 38.9)	78.5 (66.9 to 90.5)	-35.7 (-48.2 to -22.3)

DALYs=disability-adjusted life-years. UI=uncertainty interval.

**Table 2: Global cancer incidence, death, and DALY counts and age-standardised rates in 2023 and percentage change in counts and age-standardised rates between 1990 and 2023 for all ages and sexes combined**

(appendix 2 p 18). Behavioural risk factors were the greatest Level 1 contributor to risk-attributable cancer deaths globally in 2023, greater than environmental and occupational or metabolic risk categories. Tobacco was the leading Level 2 risk factor for cancer-attributable deaths overall, at 21.4% (18.8–24.3; appendix 2 pp 10–12, 19). Risk factors contributing to cancer burden differed widely by cancer type, with tobacco contributing to 16 cancers, high alcohol use to ten cancers, dietary risk to six cancers, and unsafe sex solely contributing to one cancer (table 3). Risk-attributable cancer deaths also varied by World Bank income group, greatest in the

upper-middle-income group (45.5% [41.0–50.1]) and lowest in the low-income group (31.3% [26.6–35.7]; appendix 2 p 18). Tobacco was the leading Level 2 risk factor for risk-attributable cancer deaths in each World Bank income group except for the low-income group, in which the leading risk factor was unsafe sex (appendix 2 p 19). A greater proportion of global cancer deaths in 2023 were attributable to estimated risk factors for males (46.0% [41.9–50.3]) than females (36.3% [31.7–40.8]; appendix 2 p 18). For males globally in 2023, the leading three Level 2 risk factors contributing to cancer deaths were tobacco, dietary risk factors, and



**Figure 1: Global age-specific cancer (A) incidence and (B) mortality in 2023 for all sexes combined**

Results are presented by 5-year age group. Left panels present age-specific incidence and mortality rates. Right panels present age-specific new case and death proportions. Several causes are not presented to not duplicate burden: eye cancer (Level 3); non-Hodgkin lymphoma (Level 3); leukaemia (Level 3); and liver cancer due to hepatitis B, liver cancer due to hepatitis C, liver cancer due to alcohol use, liver cancer due to non-alcoholic steatohepatitis, liver cancer due to other causes, and hepatoblastoma (Level 4).

high alcohol use, and for females they were tobacco, unsafe sex, and dietary risk factors (appendix 2 p 20).

The percentage of cancer deaths which were estimated to be risk-attributable remained similar over time, changing from 42.2% (95% UI 37.7 to 47.6)

in 1990 to 42.0% (37.6 to 47.0) in 2000, and 42.3% (38.2 to 46.3) in 2010 (GBD Results Tool).

This change over time was equivalent to a -1.1% (-6.6 to 4.2) change in attributable fractions from 1990 to 2023. The leading three Level 2 risk

	Total risk attributable DALYs, % (95% UI)	Tobacco attributable DALYs, % (95% UI)	Dietary risk attributable DALYs, % (95% UI)	High alcohol use attributable DALYs, % (95% UI)	Unsafe sex attributable DALYs, % (95% UI)	Other risk attributable DALYs, % (95% UI)
Total cancers excluding non-melanoma skin cancer	40.3 (36.4 to 43.9)	19.9 (17.5 to 22.5)	6.6 (2.2 to 11.0)	3.6 (2.0 to 5.4)	4.9 (3.8 to 6.2)	14.7 (12.3 to 17.6)
Lip and oral cavity cancer	39.4 (32.2 to 47.0)	35.4 (28.2 to 43.3)	NA	6.8 (1.9 to 11.8)	NA	NA
Nasopharynx cancer	21.9 (17.2 to 27.2)	21.0 (16.4 to 26.2)	NA	NA	NA	1.0 (0.7 to 1.4)
Other pharynx cancer	51.9 (44.7 to 59.1)	43.2 (35.9 to 51.3)	NA	16.5 (13.9 to 18.9)	NA	NA
Oesophageal cancer	56.9 (42.0 to 70.0)	38.1 (32.0 to 44.6)	14.3 (-2.7 to 29.5)	19.6 (-0.8 to 43.3)	NA	NA
Stomach cancer	18.9 (10.3 to 48.7)	11.2 (9.1 to 13.8)	7.2 (0.0 to 40.8)	1.7 (-0.7 to 3.5)	NA	NA
Colon and rectum cancer	55.5 (41.3 to 67.2)	4.8 (3.0 to 6.9)	37.1 (18.2 to 53.4)	5.2 (2.2 to 8.9)	NA	23.8 (18.5 to 29.2)
Liver cancer	46.4 (40.4 to 53.1)	10.8 (3.6 to 18.8)	NA	19.8 (15.8 to 25.9)	NA	24.8 (18.1 to 31.2)
Gallbladder and biliary tract cancer	11.9 (7.7 to 15.7)	NA	NA	NA	NA	11.9 (7.7 to 15.7)
Pancreatic cancer	38.6 (33.7 to 44.6)	15.6 (13.8 to 17.4)	NA	2.1 (0.4 to 2.9)	NA	26.1 (19.4 to 33.5)
Larynx cancer	72.9 (67.1 to 78.0)	68.3 (62.9 to 73.6)	NA	12.5 (3.0 to 23.0)	NA	5.7 (3.4 to 8.7)
Tracheal, bronchus, and lung cancer	77.0 (73.7 to 80.4)	62.9 (59.0 to 66.7)	4.7 (2.3 to 7.4)	NA	NA	39.5 (29.9 to 49.1)
Breast cancer	28.1 (16.5 to 38.8)	7.5 (5.2 to 9.9)	10.8 (0.0 to 23.4)	2.2 (1.1 to 3.5)	NA	11.7 (7.3 to 16.1)
Cervical cancer	100.0 (100.0 to 100.0)	5.9 (3.2 to 9.3)	NA	NA	100.0 (100.0 to 100.0)	NA
Uterine cancer	33.7 (24.2 to 42.3)	NA	NA	NA	NA	33.7 (24.2 to 42.3)
Ovarian cancer	9.9 (4.4 to 15.6)	NA	NA	NA	NA	10.1 (4.5 to 15.8)
Prostate cancer	1.6 (-5.6 to 6.8)	3.6 (1.6 to 5.9)	-3.7 (-10.2 to 2.0)	1.6 (0.1 to 3.6)	NA	NA
Kidney cancer	27.1 (17.0 to 36.7)	9.4 (5.9 to 13.4)	NA	NA	NA	19.7 (8.6 to 29.6)
Bladder cancer	34.6 (29.7 to 39.8)	27.3 (23.1 to 31.2)	NA	NA	NA	10.2 (6.1 to 15.1)
Thyroid cancer	11.4 (7.9 to 15.8)	NA	NA	NA	NA	11.4 (7.9 to 15.8)
Mesothelioma	84.9 (81.5 to 88.2)	NA	NA	NA	NA	84.9 (81.5 to 88.2)
Non-Hodgkin lymphoma	4.3 (1.4 to 7.1)	NA	NA	NA	NA	4.3 (1.4 to 7.1)
Multiple myeloma	7.6 (-3.4 to 17.4)	NA	NA	NA	NA	7.6 (-3.4 to 17.4)
Leukaemia	13.3 (9.5 to 17.8)	6.5 (2.3 to 11.0)	NA	NA	NA	7.6 (5.5 to 10.0)

The leading four Level 2 risk factors contributing to cancer DALYs for both sexes combined in 2023 are separately reported. The remainder of risk factors are presented in the "other risk-attributable DALYs" column. Causes without any risk-attributable DALYs include malignant skin melanoma; soft tissue and other extrasosseous sarcomas; malignant neoplasm of bone and articular cartilage; testicular cancer; brain and CNS cancer; eye cancer; neuroblastoma and other peripheral nervous cell tumours; Hodgkin lymphoma; other malignant neoplasms; and other neoplasms. Details on risk-attributable burden estimation are available in the Methods section of this Article and in other publications.<sup>2</sup> The total column value might be smaller than the sum of the risk factor columns because it accounts for overlapping risk exposures when applicable (including when the "Other" column contains multiple risk factors, such as for ovarian cancer). Negative values in this table can occur when risk factors are protective. DALYs=disability-adjusted life-years. UI=uncertainty interval. NA=not applicable, because GBD 2023 does not estimate these risk factor-cancer combinations.


**Table 3: Global proportion of DALYs attributable to risk factors by cancer cause for all ages and sexes combined**

factors for both sexes combined in 1990 were tobacco, dietary risks, and air pollution, while in 2023 they were tobacco, dietary risks, and high fasting plasma glucose (GBD Results Tool).

### Trends in cancer burden, 1990–2023

Between 1990 and 2023, for males and females combined, new cancer cases increased by 105.1% (95% UI 79.5 to 137.4), and cancer deaths increased by 74.3% (62.2 to 86.2). In contrast, age-standardised mortality rates due to cancer were estimated to have decreased between 1990 and 2023, by 23.9% (19.1 to 29.1), whereas age-standardised incidence rates changed

by -7.1% (-18.4 to 7.4; table 1). Global age-standardised cancer mortality rates decreased similarly in males and females between 1990 and 2023 (appendix 2 pp 13–14). Among World Bank income groups, the largest decline in age-standardised mortality rates occurred in the upper-middle-income group, a 33.5% (25.7 to 41.4) decline, followed by the high-income group (27.3% [25.5 to 30.1] decline), whereas increases in age-standardised mortality rates occurred in the lower-middle-income group (16.6% [3.9 to 32.8]) and were suggestive in the low-income group (14.2% [-0.3 to 31.1]; table 1). Cancer was the second leading Level 2 cause of death within the GBD cause



**Figure 2:** Cancer (A) incidence and (B) mortality in age-standardised rates and counts between 2024 and 2050 globally and by World Bank income group for all ages and sexes combined

hierarchy and age-standardised mortality rates globally in 2023, and was consistently ranked second from 1990 to 2023 with the exception of 2021, when respiratory infections and tuberculosis (which include COVID-19) were ranked second, following cardiovascular disease (GBD Results Tool).<sup>24</sup>

#### Cancer burden in the future up to 2050

The global number of cancer cases and deaths was forecasted to rise between 2024 and 2050 by 60.7% (95% UI 41.9 to 80.6) and 74.5% (50.1 to 104.2), respectively, from 19.0 million (16.8 to 21.2) to 30.5 million (22.9 to 38.9) and from 10.6 million (9.92 to 11.2) to 18.6 million (15.6 to 21.5; figure 2; appendix 2 pp 20–21). DALYs were forecasted to increase by 46.2% (29.8 to 67.2), from 276 million (260 to 290) to 404 million (356 to 455). Age-standardised cancer incidence and mortality rates were forecasted to change between 2024 and 2050 by –5.7% (–12.4 to 1.6, from 204.6 [180.9 to 228.8] to 192.9 [157.0 to 232.5]) and –5.6% (–12.8 to 4.6, from 114.2 [106.3 to 120.6] to 107.9 [96.7 to 119.4]), suggesting that most of the increases in cases and deaths are due to demographic changes (figure 2; appendix 2 pp 20–21). These forecasts were also used to estimate progress of the cancer component of UN SDG target 3.4, which aims by 2030 to reduce premature

mortality by a third from non-communicable diseases between ages 30 and 70 years. Between 2015 and 2030, the probability of death from cancer between ages 30 and 70 years is forecasted to decrease from 7.0% (6.7 to 7.3) in 2015 to 6.5% (6.0 to 7.1) in 2030. The forecasted relative decrease of 6.5% (3.2 to 10.3) in the probability of death from cancer suggests that currently forecasted cancer reductions are unlikely by themselves to meet the SDG target.

The three leading cancer types for deaths globally in 2024 (tracheal, bronchus, and lung cancer; colon and rectum cancer; and stomach cancer), are each forecasted to have an increasing number of deaths globally up to 2050, increasing by 62.5% (95% UI 26.2 to 104.0), 93.5% (42.2 to 154.7), and 22.5% (12.3 to 33.1), to 3.39 million (2.57 to 4.29), 2.21 million (1.54 to 3.07), and 1.16 million (0.959 to 1.30), respectively (appendix 2 pp 22–23). Global age-standardised mortality rates are forecasted to decrease for stomach cancer (36.0% [32.6 to 39.4] decrease), whereas age-standardised mortality rates for tracheal, bronchus, and lung cancer and colon and rectum cancer are forecasted to change by –15.2% (–28.9 to 1.1) and –2.0% (–21.7 to 21.5), respectively. Continuing declines in age-standardised mortality rates for lung and stomach cancer are forecasted for each of the four World

Bank income groups, even though for lung cancer only the high-income group shows a significant decline while all four income groups show a significant decline for stomach cancer. For colon and rectum cancers forecasts, there is a trend towards a modest decline in the high-income group and increases in the other income groups, but with wide uncertainty intervals. For breast, cervical, and childhood cancers, the three cancer types that are part of WHO initiatives to improve global cancer outcomes,<sup>10–12</sup> forecasts suggest mixed progress by 2050 that varies by World Bank income group. For cervical cancer and childhood cancers, forecasts suggest modest declines in the age-standardised mortality rates globally, with the largest decreases in the high-income group (25.0% [19.2 to 30.4] decrease and 18.0% [9.8 to 24.6] decrease, respectively). For breast cancer, forecasts suggest a stable age-standardised death rate globally, and a decline in higher World Bank income groups while lower World Bank income groups experience an increase, although both with wide uncertainty intervals (appendix 2 pp 22–23).

## Discussion

Cancer is an increasing global health problem, with rising numbers of cases and deaths affecting health systems worldwide. Cancer is one of four target disease groups in the WHO Global Action Plan for the Prevention and Control of NCDs,<sup>36,37</sup> as well as a cornerstone of UN Sustainable Development Goal target 3.4.<sup>13</sup> However, progress towards reducing mortality from cancer and other NCDs is not occurring rapidly enough to achieve established targets globally, and the COVID-19 pandemic has disrupted cancer care and shifted international focus and funding.<sup>15–17,38–40</sup>

We found that cancer deaths increased over the past three decades and are forecasted to continue to increase up to 2050. Between 1990 and 2023, the global age-standardised cancer mortality rate decreased by 23.9% (95% UI 19.1 to 29.1) whereas the age-standardised incidence rate changed by  $-7.1\%$  ( $-18.4$  to  $7.4$ ), indicating modest improvement in case-fatality rates over this three-decade period. However, progress in the probability of cancer death in ages 30–70 years appears to be an insufficient contribution to the SDG target of a reduction in NCD deaths by a third between 2015 and 2030. Cancer has consistently ranked as the second-leading cause of death globally across the past three decades, including in 2023, with the exception of 2021, when deaths from COVID-19 pushed the respiratory infections and tuberculosis group to rank second.<sup>24</sup> While age-standardised mortality rates of cancer between 1990 and 2023 decreased globally, the decrease was limited to the World Bank high-income and upper-middle-income groups. Simultaneously, the low-income and lower-middle-income groups had the largest increases in age-standardised mortality rates and the largest percentage increases in cancer deaths over this period. This highlights

a developing cancer challenge in settings with limited resources and an obligation of the global health community to prioritise equitable cancer-control efforts.

Of the 10.4 million cancer deaths estimated in 2023, 41.7% (95% UI 37.8–45.4) of these were attributable to risk factors included in the GBD 2023 analysis. Reducing exposure to potentially modifiable risk factors could help reduce future cancer burden. However, these GBD estimates do not currently account for several infectious diseases known to be causally associated with cancers and that are more common in low-income countries, resulting in likely underestimates of risk-attributable cancer burden. Although some previous work has captured cancer burden attributable to infections such as with Epstein–Barr virus,<sup>41</sup> future work is needed to incorporate this and other infectious agents into the full GBD risk factor hierarchy. There was also a substantial portion of cancer deaths estimated to not be avoidable based on currently captured risk factors in the GBD study. This suggests that a combination of interventions addressing exposure to established cancer risk factors, accurate and timely cancer diagnosis, and quality cancer treatment will be needed to simultaneously support individuals developing cancer, while working towards reducing future cancer burden across all settings.

In spite of the substantial and growing contribution of NCDs to the global disease burden, they have received relatively little funding in global health in comparison to communicable diseases.<sup>39,42,43</sup> Cancers represent a large share of the NCD burden. This discrepancy between burden and funding highlights the need for more monetary support dedicated towards reducing NCDs, including cancer, in the global health arena, as many countries are faced with the double burden of communicable and non-communicable diseases. Insufficiently funding efforts to reduce a major contributor to global disease burden will perpetuate the current disparities, which are evident when comparing cancer outcomes between countries around the world.<sup>44–46</sup> While the ongoing SDG work is an important motivator and target, much stronger efforts to reduce cancer burden are needed, which will require higher than current levels of funding and prioritisation to be successful.<sup>38,43</sup>

Another necessary component for reducing the burden of cancer is the development of well-functioning health systems that are equipped to address the entire cancer continuum, from prevention, screening, and treatment to palliative care or survivorship. Such broad requirements can make effective cancer care seem complex and challenging, particularly in lower-resource settings. However, there are established strategies for developing and implementing national cancer-control plans.<sup>47,48</sup> Ideally, such plans are informed by all stakeholders and use established monitoring and evaluation strategies. Essential packages for cost-effective interventions addressing cancer control have been

proposed as part of the Disease Control Priorities recommendations for low-income and middle-income countries, and WHO has produced summary recommendations of best buys for cost-effective cancer services.<sup>49–51</sup> Cancer often affects caregivers and families beyond the individual diagnosed with cancer, and cancer treatment has the potential to be financially and psychosocially devastating in countries across the resource spectrum.<sup>52–56</sup> Universal health coverage that includes cancer screening where relevant, diagnosis, treatment, and health care for survivors is crucial to ensuring financial protection for families, access to early identification and care, and equity in outcomes.<sup>57,58</sup>

In addition, there are potential synergies of cancer prevention and care with NCDs more broadly; an investment in certain aspects of capacity to prevent, detect, and treat cancer overlaps with other areas of intervention to address growing NCD burden. Beyond aspects of health system strengthening and financial protections for NCD care, addressing social, environmental, and commercial determinants of health and risk factors for cancers offers opportunities for prevention of a subset of cancers.<sup>59–61</sup> Several common cancer types globally are associated with risk factors that have opportunities for mitigation. For example, smoking is associated with lung cancer; this risk factor could potentially be reduced through taxation policies.<sup>62,63</sup> Another example is cervical cancer, which is linked to high-risk types of human papillomavirus. Vaccination initiatives have the potential to reduce cervical cancer burden,<sup>64,65</sup> particularly when combined with screening efforts to identify cancers in early stages, where it is feasible and ethical to do so.<sup>66,67</sup> Tobacco use, high alcohol intake, an elevated BMI, low physical activity, an unhealthy diet, and air pollution are shared risk factors across multiple cancer types as well as other NCDs, with substantial potential for reducing mortality due to NCDs if effectively addressed.<sup>68</sup> Changes in climate across the world may further alter exposure to risk factors for cancer and other NCDs in the coming years, in addition to disrupting access to treatment, with potential benefits of addressing these environmental impacts across NCDs. Underscoring the importance of decreased exposure to cancer risk factors as one facet of a comprehensive approach to addressing cancer burden should not be conflated with ascribing fault to individual patients who develop cancer types associated with these risk factors. Many behaviours and environmental exposures are influenced by economic factors, the built environment, social policies and norms, and other social determinants of health. Thus, reducing the burden of cancer across countries and worldwide will require both individual action and effective population-level approaches to reduce risk exposures.<sup>69</sup>

Our estimates of total global cancer deaths and incident cases for GBD 2023 are most comparable to the 2022 estimates by GLOBOCAN.<sup>22</sup> GBD 2023 estimated

18·5 million cancer cases and 10·4 million cancer deaths in 2023, and GLOBOCAN estimated 18·7 million cancer cases and 9·7 million cancer deaths in 2022.<sup>22,70</sup> There are several differences in the cancer-specific estimates produced by GBD 2023 and GLOBOCAN 2022. Both GBD and GLOBOCAN found that lung cancer and colon and rectum cancer were the first-leading and second-leading causes of cancer mortality, respectively, but with variation in ranking of following cancer causes of death. Although GBD estimated breast cancer as the leading cause of new cancer cases in 2023, followed by lung and colorectal cancer, GLOBOCAN estimated that lung cancer was the leading cause of new cancer cases in 2022, with breast cancer second and colorectal cancer third. These differences in estimates most likely stem from differences in data sources, data processing, and modelling strategies. For example, GBD 2023 redistributed non-specific cause of death codes to more specific underlying causes of death, including cancers,<sup>71</sup> to account for all causes of death in a population. These differences underscore the importance of supporting high-quality cancer surveillance efforts internationally, as estimates are only as reliable as the data informing them. The Global Initiative for Cancer Registry Development is one important example of coordinated international efforts to establish and improve cancer registration endeavours.<sup>72</sup> The effective and sufficient allocation of resources to support cancer data surveillance will be important for accurate cancer burden information and policy implementation. There are additional differences between GBD 2023 and GLOBOCAN 2022, with both presenting burden estimates for some cancer types not estimated by the other, and GBD 2023 producing cancer burden estimates that include DALYs and generating global estimates across time since 1990. GBD 2023 also provides the ability to compare cancer burden to the burden of other diseases in the same framework of estimation.

GLOBOCAN has provided estimates of cancer incidence attributable to individual cancer risk factors in individual years of estimation, such as alcohol in 2020<sup>73</sup> and obesity in 2012,<sup>74</sup> but has not produced a comprehensive summary of risk-attributable cancer burden in the same year that allows for comparison to the GBD results presented here. GLOBOCAN 2022 also forecasted cancer incidence and mortality up to 2050,<sup>75</sup> assuming constant rates and informed by demographic projections. In contrast, the GBD 2023 forecasting framework includes time and independent drivers of disease to forecast cancer mortality, then uses forecasted mortality-to-incidence ratios and disability weights to forecast cancer incidence and DALYs. A key feature of the GBD forecasting framework is that the cause-specific mortality forecasts are directly informed by future risk factor exposures that are deemed causally linked to each cancer according to the GBD comparative risk assessment. GBD forecasts also provide the opportunity

to evaluate alternative scenarios that can inform policy decisions, such as eliminating exposure to behavioural and metabolic risk factors by 2050. This, as well as forecasts of additional cancer burden measures such as YLLs, YLDs, and DALYs up to 2050 are available online in the GBD forecasting viz tool. The GLOBOCAN forecasts estimate that there will be 32.6 million cancer cases and 18.3 million deaths in 2050,<sup>75</sup> whereas the GBD forecasts estimate that there will be 30.5 million cancer cases and 18.6 million deaths in 2050, both excluding non-melanoma skin cancers. Apart from GBD's explicit modelling of risk factors of future cancer burden, the differences between these estimates could also be due to the differences in population projections by the UN Population Division, used by GLOBOCAN, and those made for GBD, the latter of which do not incorporate an unlikely assumption of reversal of fertility declines.<sup>32</sup> In both sets of forecasts, it is clear that global cancer estimation groups predict substantial coming cancer burden if interventions are not intensified and underscore the importance of addressing cancer across the international spectrum of resource availability.

The cancer types newly incorporated in GBD 2021 were particularly relevant to cancer cases and deaths in the childhood and adolescent age groups, and several new cancer types added are index cancers selected for monitoring of progress towards the WHO Global Initiative for Childhood Cancer goals,<sup>10</sup> which aim to reach 60% survival and reduce suffering for all children with cancer globally. Trends in global cancer burden among younger age groups will be explored in a separate manuscript. A cancer diagnosis often does not affect only the individual with cancer. Caregivers contribute time and emotional and physical labour that is often uncompensated financially.<sup>76</sup> More broadly, a cancer diagnosis can lead to negative effects beyond just the health ramifications, such as disruptions to family finances, employment, or housing security due to health-care costs;<sup>52–56</sup> stigma,<sup>77</sup> which may impede other family members seeking medical care; or the death of a single parent, which can contribute to children being orphaned.<sup>78</sup> Ultimately, these family-level and community-level challenges underscore that, as cancer burden continues to grow, there will be a growing need for support systems that expand beyond an individual patient with cancer and consider the family and community.

There were limitations to our analysis, many of which are areas for potential future improvements in the GBD study, depending on data availability. Apart from scarce vital registration data on cancer deaths in the early period of the COVID-19 pandemic, GBD 2023 cancer estimates and forecasts did not incorporate the effect of the COVID-19 pandemic or recent conflicts on cancer burden, as these data were not available in a geographically and temporally robust and diverse way at the time of our analysis. We hope to be able to understand

the effect of COVID-19 on cancer in future analyses as these data become more available over time. Data availability and quality in general can be a challenge, with sparse data from some countries and years. While verbal autopsy studies can help contribute additional information in data-sparse locations, these studies may vary in their ability to accurately capture mortality. For this reason, verbal autopsy data were used for a limited number of cancer types and locations, and the effect of these data is expected to be minimal for most cancer estimates. Uncertainty estimates are provided with all GBD cancer results, but estimates should be interpreted with consideration of data sparsity, and producing statistical estimates of cancer burden does not supplant the need for continued and expanded support of cancer registries and vital registration systems. Furthermore, forecasts of future cancer burden cannot account for potential discoveries and implementation changes in cancer diagnosis and treatment that are currently unknown, and should be interpreted with caution. GBD estimates do not incorporate cancer burden attributable to several infectious diseases, such as *Helicobacter pylori* or *Schistosoma haematobium*, which weigh more heavily on lower-income countries, and therefore likely underestimate risk-attributable cancer burden in those settings. Lifelong burden from surviving cancer is not incorporated into GBD beyond the effect of permanent surgical procedures such as mastectomy, which likely contributes to an underestimation of cancer morbidity, most notably in childhood cancer survivors.

## Conclusion

The global burden of cancer is large and increasing—and expected to continue increasing up to 2050—with disproportionate growth occurring in lower-resource settings. The decline in age-standardised mortality rates from cancer is encouraging but insufficient to meet the SDG target set for a reduction in NCD mortality by a third between 2015 and 2030. The findings from this analysis show that it is imperative that greater efforts are made to prevent, diagnose, and treat cancer across world regions and economically diverse settings. Despite the clear need for action, there remains a gap in funding and prioritisation of cancer-control policies in global health. Policy makers, governments, and agencies can use these GBD estimates and forecasts in the development and implementation of evidence-based strategies across the cancer continuum locally, nationally, regionally, and globally.

### GBD 2023 Cancer Collaborators

Lisa M Force\*, Jonathan M Kocarnik, Miranda L May, Kayleigh Bhangdia, Andrew Crist, Louise Penberthy, Natalie Pritchett, Alistair Acheson, Lee Deitesfeld, Bhoomadevi A, Hasan Aalruz, Nasir Abbas, Maryam Abbasalipour Bashash, Abdallah H A Abd Al Magied, Samar Abd ElHafeez, Ashraf Nabil Abdalla, Mohammed Altigani Abdalla, Wael M Abdel-Rahman, Parsa Abdi, Waggari Mosisa Abdissa, Daba Abdissa, Arash Abdollahi, Meriem Abdoun, Arman Abdous,

For more on the GBD forecasting viz tool see <https://vizhub.healthdata.org/gbd-foresight/>

- Auwal Abdullahi, Mesfin Abebe, Armita Abedi, Syed Hani Abidi, Alemwork Abie, Olumide Abiodun, Richard Gyan Aboagye, Hassan Abolhassani, Ulric Sena Abonie, Lucas Guimarães Abreu, Aminu Kende Abubakar, Bilyaminu Abubakar, Eman Abu-Gharbieh, Hana J Abukhdajah, Salahdein Aburuz, Ahmed Abu-Zaid, Raghu Ram Achar, Juan Manuel Acuna, Lisa C Adams, Lawan Hassan Adamu, Isaac Yeboah Addo, Kamoru Ademola Adedokun, Nurudeen A Adegoke, Victor Adekanmbi, Ibukun Modupe Adesiyin, Habeeb Omoponle Adewuyi, Usha Adiga, Qorinah Estiningtyas Sakilah Adnani, Prince Owusu Adoma, Leticia Akua Adzigbli, Ahmed M Afifi, Aanuoluwapo Adeyimika Afolabi, Fatemeh Afrashteh, Arya Afrooghe, Muhammad Sohail Afzal, Suneth Buddhika Agampodi, Navidha Aggarwal, Feleke Doyore Agide, César Agostinis Sobrinho, Williams Agyemang-Duah, Bright Opoku Ahinkorah, Aqeel Ahmad, Danish Ahmad, Faisal Ahmad, Khurshid Ahmad, Muayyad M Ahmad, Sajjad Ahmad, Tauseef Ahmad, Elham Ahmadi, Amir Mahmoud Ahmadzade, Mohadese Ahmadzade, Anisuddin Ahmed, Ayman Ahmed, Gasha Salih Ahmed, Ibrar Ahmed, Luai A Ahmed, Mehrunnisha Sharif Ahmed, Meqdad Saleh Ahmed, Muktar Beshir Ahmed, Nesredin Ahmed, Syed Anees Ahmed, Dolapo Emmanuel Ajala, Marjan Ajami, Roland Eghoghoso Akhigbe, Karolina Akinosoglou, Salah Al Awaidey, Hanadi Al Hamad, Syed Mahfuz Al Hasan, Omar Al Omari, Mohammad Al Qadire, Yazan Al Thaher, Omar Ali Mohammed Al Zaabi, Khurshid Alam, Zufishan Alam, Amani Alansari, Fahmi Y Al-Ashwal, Laila Ismael Al-Daken, Wafa A Aldhaleei, Shereen M Aleidi, Bezawit Abeje Alemayehu, Ayman Al-Eyadhy, Abdelazeem M Algammal, Adel Ali Saeed Al-Gheethi, Mohammed Khaled Al-Hanawi, Dari Alhuwail, Abid Ali, Endale Alemayehu Ali, Mohammad Daud Ali, Mohammed Usman Ali, Rafat Ali, Syed Shujait Ali, Waad Ali, Sheikh Mohammad Alif, Samah W Al-Jabi, Syed Mohamed Aljunid, Ahmad Alkhatib, Nihad A Almasri, Hesham M Al-Mekhlafi, Mohammad Minwer Alnaeem, Hasan Yaser Alniss, Margaret Beaula Alocious Sukumar, Mahmoud A Alomari, Mohammad R Alosta, Saleh A Alqahtani, Ahmad Rajeh Al-Qudimat, Rajaa M Mohammad Al-Raddadi, Ahmad Alrawashdeh, Intima Alrimawi, Sahel Majed Alrousan, Salman Khalifah Al-Sabah, Najim Z Alshahrani, Awais Altaf, Alaa B Al-Tammemi, Elysia M Alvarez, Nelson Alvis-Guzman, Yaser Mohammed Al-Worafi, Hany Aly, Mohammad Sharif Ibrahim Alyahya, Abdallah Alzoubi, Kareem H Alzoubi, Md Akib Al-Zubayer, Masoud Aman Mohammadi, Tarek Tawfik Amin, Alireza Aminardolzarbi, Shiva Aminnia, Nafiu Aminu, Mohammad Hosein Amirzade-Iranaq, Hubert Amu, Ganiyu Adeniyi Amusa, Robert Ancuceanu, Deanna Anderlini, Abhishek Anil, Amir Anoushiravani, Hossein Ansarinia, Iyadunni Adesola Anuoluwa, Saeid Anvari, Saleha Anwar, Sumadi Lukman Anwar, Raziq Anwer, Ekenedilichukwu Emmanuel Anyabolo, Anayochukwu Edward Anyasodor, Angela Esi Apeagyei, Juan Pablo Arab, Jalal Arabloo, Razman Arabzadeh Bahri, Elshaimaa A Arafat, Mosab Arafat, Aleksandr Y Aravkin, Martina Arcieri, Demelash Areda, Hany Ariffin, Mesay Arkew, Anton A Artamonov, Santhosh Arul, Deepavalli Arumuganainar, Mohammad Asghari-Jafarabadi, Akram Ashames, Muhammad Abdul Basit Ashraf, Tahira Ashraf, Bernard Kwadwo Yeboah Asiamah-Asare, Haftu Asmerom Asmerom, Batyrbek Assembekov, Smita Asthana, Prince Atorkey, Maha Moh'd Wahbi Atout, Julie Alaere Atta, Marcel Ausloos, Atalel Fentahun Awedew, Adedapo Wasiu Awotidebe, Beatriz Paulina Ayala Quintanilla, Haleh Ayatollahi, Seyed Mohammad Ayyoubzadeh, Ali Azarگونjahromi, Amiral Azimi, Mohd Yusmaide Aziz, Sadat Abdulla Aziz, Shaikkar Aziz, Hosein Azizi, Ahmed Y Azzam, Muhammad Badar, Ashish D Badiye, Alaa Aboelnour Badran, Nasser Bagheri, Fereshteh Baghizadeh, Razieh Bahreini, Ruhai Bai, Atif Amin Baig, Lovenish Bains, Ram Chandra Bajpai, Shankar M Bakkannavar, Auwal Adam Bala, Wondu Feyisa B alcha, Mohammadreza Balooch Hasankhani, Soham Bandyopadhyay, Rajon Banik, Aleksandra Barac, Shirin Barati, Mainak Bardhan, Suzanne Lyn Barker-Collo, Hiba Jawdat Barqawi, Amadou Barrow, Zarrin Basharat, Shahid Bashir, Afisu Basiru, Pritish Baskaran, Mohammad-Mahdi Bastan, Kavita Batra, Matteo Bauckneht, Mohsen Bayati, Feyisa Shasho Bayisa, Narasimha M Beeraka, Babak Behnam, Amir Hossein Behnoush, Payam Behzadi, Diana Fernanda Bejarano Ramirez, Sewunet admasu Belachew, Gokce Belge Bilgin, Luis Belo, Habib Benzian, Alemshet Yirga Berhie, Amiel Nazer C Bermudez, Ajeet Singh Bhadoria, Akshaya Srikanth Bhagavathula, Nickhill Bhakta, Neeraj Bhala, Ravi Bharadwaj, Nikha Bhardwaj, Pankaj Bhardwaj, Prarthna V Bhardwaj, Sonu Bhaskar, Ajay Nagesh Bhat, Vivek Bhat, Shuvarthi Bhattacharjee, Gurjit Kaur Bhatti, Jasvinder Singh Bhatti, Mohiuddin Ahmed Bhuiyan, Soumitra S Bhuyan, Raluca Bievel-Radulescu, Cem Bilgin, Catherine Bisignano, Mohammad Shahangir Biswas, Monirujjaman Biswas, Bruno Bizzozero-Peroni, Tone Bjørge, Trupti Bodhare, Obasanjo Afolabi Bolarinwa, Archith Bolor, Hamed Borhany, Samuel Adolf Bosoka, Alejandro Botero Carvajal, Souad Bouaoud, Marija M Bozic, Dejana Braithwaite, Michael Brauer, Hermann Brenner, Linh Phuong Bui, Katrin Burkart, Felix Busch, Maria Teresa Bustamante-Teixeira, Yasser Buntanji, Nadeem Shafique Butt, Zahid A Butt, Guangyao Cai, Luis Alberto Cámara, Ismael Campos-Nonato, Si Cao, Yubin Cao, Angelo Capodici, Giulia Carreras, Márcia Carvalho, Carlos A Castañeda-Orjuela, Ferrán Catalá-López, Maria Sofia Cattaruzza, Luca Cegolon, Francieli Cembranel, Ester Cerin, Achille Cernigliaro, Sonia Cerrai, Aditya Chakraborty, Chiranjib Chakraborty, Sandip Chakraborty, Rama Mohan Chandika, Vijay Kumar Chattu, Anis Ahmad Chaudhary, Sirshendu Chaudhuri, Akhilanand Chaurasia, Galmesa Bekana Chemedda, Hana Chen, Kai Chen, Meng Xuan Chen, Fatemeh Chichagi, Odgerel Chimed-Ochir, Patrick R Ching, Jesus Lorenzo Chirinos-Caceres, William C S Cho, Dong-Woo Choi, Sungchul Choi, Bryan Chong, Yuen Yu Chong, Hitesh Chopra, Shivani Chopra, Hou In Chou, Sonali Gajanan Choudhari, Dinh-Toi Chu, Isaac Sunday Chukwu, Eric Chung, Sunghyun Chung, Iolanda Cioffi, Alyssa Columbus, Joao Conde, Vera Marisa Costa, Natalia Cruz-Martins, Bashir Dabo, Ormid Dadras, Xiaochen Dai, Lalit Dandona, Rakhi Dandona, Lucio D'Anna, Pojsakorn Danpanichkul, Reza Darvishi Cheshmeh Soltani, Aso Mohammad Darwesh, Saswati Das, Nihar Ranjan Dash, Mohsen Dashti, Cornelius Dassah, Dimash Davletov, Fernando Pio De la Hoz, Frances E Dean, Edward Christopher Dee, Sindhura Deekonda, Mohammad Delsoz, Abel Desalegn Demeke, Edgar Denova-Gutiérrez, Rupak Desai, Aragaw Tesfaw Desale, Gashaw Dessie, Devananda Devegowda, Syed Masudur Rahman Dewan, Arkadeep Dhali, Amol S Dhane, Meghnath Dhimal, Sameer Dhingra, Bibha Dhungel, Marcello Di Pumpo, Luis Antonio Diaz, Michael J Diaz, Thao Huynh Phuong Do, Saeid Doaei, Francesco Dondi, Fariba Dorostkar, Wendel Mombaqué dos Santos, Ojas Prakashbhai Doshi, Leila Doshmangir, Taiwo Omotayo Dosumu, Robert Kokou Dowou, Menayit Tamrat Dresse, John Dube, Senbagam Duraisamy, Oyewole Christopher Durojaiye, Sulagna Dutta, Arkadiusz Marian Dziedzic, Abdel Rahman Emar, Hisham Atan Edinur, Behrad Eftekhari, Ashkan Eighaei Sedeh, Michael Ekholuenetale, Temitope Cyrus Ekundayo, Rabie Adel El Arab, Abdelfatteh EL Omri, Iman El Sayed, Maysaa El Sayed Zaki, Reza Elahi, Noha Mousaad Elemam, Muhammed Elhadi, Waseem El-Huneidi, Sherif Elkannishy, Ahmed O Elmehrath, Adel B Elmoselhi, Randa Elsheit, Yasser Mohamed El-Sherbiny, Ibrahim Elsohaby, Abdelgawad Salah Abdelgawad Eltahaw, Mohd Elmagzoub Elthahir, Syed Emdadul Haque, Theophilus I Emeto, Talha Bin Emran, Destaw Endeshaw, Babak Eshtrati, Majid Eslami, Sayeh Ezzikouri, Heidar Fadavian, Adeniyi Francis Fagbamigbe, Aysha Fahim, Saman Fahimi, Aamir Fahira, Ildar Ravisovich Fakhradiyev, Aliasghar Fakhri-Demeshgheh, Luca Falzone, Alireza Farahani, Mohammad Farahmand, Seyed Nooreddin Faraji, Mahsa Faramarzpour, Ebrahim Farashi, Zaki Farhana, MoezAllIslam Ezzat Mahmoud Faris, Pawan Sirwan Faris, Andre Faro, Umar Farooque, Hossein Farrokhpour, Abidemi Omolara Fasanmi, Kiana Fasih, Emmanuel Toluwani Fasusi, Hamed Fattahi, Alireza Feizkhah, Ginenus Fekadu, Daniela Ferrante, Pietro Ferrara, Nuno Ferreira, Getahun Fetensa, Florian Fischer, James L Fisher, Bobirca Teodor Florin, Olumuyiwa Shola Folan, Arianna Fornari, Ali Forouhari, Behzad Foroutan, Maryam Fotouhi,

Takeshi Fukumoto, Ami Fukunaga, Muktar A Gadanya, Márió Gajdác, Silvano Gallus, Adamu Usman Gamawa, Aravind P Gandhi, Shivaprakash Gangachannaiah, Mounika Gangireddy, Jacopo Garlasco, Rupesh K Gautam, Feven Sahle Gebre, Miglas Welay Gebregergis, Mesfin Gebrehiwot, Teferi Gebru Gebremeskel, Haftay Gebremedhin Gebreslassie, Gebremariam Wulie Geremew, Genanew K Getahun, Sadeh Ghafarian, Amir Ghaffari Jolfayi, Lobna Faiz Gharaibeh, Haniyeh Ghasrsaz, Fariba Ghassemi, Ramy Mohamed Ghazy, Maryam Gholamalizadeh, Nasim Gholizadeh, Elena Ghotbi, Konstantinos Giannakis, Artyom Urieovich Gil, Syed Abdullah Gilani, Alem Abera Girmay, Alessandro Girombelli, Amit Goel, Anil Kumar Goel, Mahaveer Golechha, Davide Golinelli, MReza Goodarzi, Giuseppe Gorini, Changhao Gu, Shi-Yang Guan, Giovanni Guarducci, Mohammed Ibrahim Mohialdeen Gubari, Zheng Guo, Zhifeng Guo, Bhawna Gupta, Sapna Gupta, Reyna Alma Gutiérrez, Jose Guzman-Esquivel, Adrina Habibzadeh, Farrokh Habibzadeh, Parham Habibzadeh, Tesfahun Simon Simon Hadaro, Najah R Hadi, Dariush Haghmorad, Nguyen Hai Nam, Haimanot Ewnetu Hailu, Hassen Mosa Mosa Halil, Islam M Hamad, Randah R Hamadeh, Nadia M Hamdy, Sajid Hameed, Nasrin Hanifi, Ashanul Haque, Josep Maria Haro, Ahmed I Hasaballah, Md Kamrul Hasan, S M Mahmudul Hasan, Fatemeh Hasani, Hamidreza Hasani, Alireza Hasanadeh, Abdiwahab Hashi, Md Saquib Hasnain, Ikrama Ibrahim Hassan, Treska S Hassan, Mahgol Sadat Hassan Zadeh Tabatabaei, Johannes Haubold, Simon I Hay, Khezar Hayat, Guohua He, Qiang He, Wen-Qiang He, Behzad Heibati, Mohammad Heidari, Claudiu Herteliu, Hamed Hesami, Majid Heydari, Mojtaba Heydari, Zahra Heydarifard, Demisu Zembaba Heyi, Kamal Hezam, Yuta Hiraike, Mai Hoang, Ramesh Holla, Nobuyuki Horita, Mehdi Hoseinzadeh, H Dean Hosgood, Alamgir Hossain, Md Mahub Hossain, Md Sabbir Hossain, Mohammad Bellal Hossain, Mohammad-Salar Hosseini, Ahmad Hosseinzadeh Adli, Mihaela Hostiuc, Vivian Chia-rong Hsieh, Chengxi Hu, Junjie Hu, Junjie Huang, Kiavash Hushmandi, Javid Hussain, Salman Hussain, Dursa Hussein, Nawfal R Hussein, Mohamed Ibrahim Husseiny, Hong-Han Huynh, Ivo Iavicoli, Segun Emmanuel Ibitoye, Reem Ibrahim, Anel Ibrayeva, Francisco Javier Idalsoaga, Pulwasha Maria Iftikhar, Adalia Ikiroma, Olayinka Stephen Ilesanmi, Irena M Ilic, Milena D Ilic, Muhana Fawwazy Ilyas, Salim Ilyasu, Mohammad Tarique Imam, Mustapha Immurana, Lucius Chidiebere Imoh, Javed Iqbal, Mustafa Alhaji Isa, Md Rabiul Islam, Faisal Ismail, Ramzy Issa, Masao Iwagami, Chidozie Declan Iwu, Mahalaxmi Iyer, Louis Jacob, Farhad Jadidi-Niaragh, Abdollah Jafarzadeh, Haiham Jahrami, Ayushi Jain, Ammar Abdulrahman Jairoun, Abhishek Jaiswal, Mihajlo Jakovljevic, Ali Jalilayan, Reza Jalilzadeh Yengejeh, Mohamed L Jalloh, Qazi Mohammad Sajid Jamal, Safayet Jamil, Syed Sarmad Javid, Talha Jawaid, Umesh Jayarajah, Shubha Jayaram, Ruwan Duminda Jayasinghe, Sun Ha Jee, Diptismita Jena, Shuai Jin, Wenyi Jin, Mohammad Jokar, Jost B Jonas, Tamas Joo, Jobin Jose, Abel Joseph, Nitin Joseph, Charity Ehimwenma Joshua, Farahnaz Joukar, Mikl Jürisson, Malik E Juweid, Anupam Jyoti, Billingsley Kaambwa, Ali Kabir, Zubair Kabir, Maryam Kabiri, Dler Hussein Kadir, Ebbie Kalan, Leila R Kalankesh, Mehnaz Kamal, Vineet Kumar Kamal, Sivesh Kathir Kamarajah, Arun Kamireddy, Ramat T Kamorudeen, Fatemeh Kanaani Nejad, Samuel Berchi Kankam, Kehinde Kazeem Kanmodi, Neeti Kapoor, Mehrdad Karajizadeh, Jafar Karami, Reema A Karasneh, André Karch, Aliasghar Karimi, Mohammad Amin Karimi, Sahand Karimzadhagh, Tomasz M Karpiński, Faizan Zaffar Kashoo, Joonas H Kauppila, Navjot Kaur, Mohd Adnan Kausar, Foad Kazemi, Fekadu Abera Kebede, Ariz Keshwani, Emmanuelle Kesse-Guyot, Yousef Saleh Khader, Himanshu Khajuria, Asaad Khalid, Hazim O Khalifa, Anita Khalili, Pantea Khalili, Alireza Khalilian, Ghazaleh Khalili-Tanha, Mohamed khalis, Faham Khamesipour, Ajmal Khan, Faiz Ullah Khan, Gulfaraz Khan, Mohammad Jobair Khan, Moien AB Khan, Salman Ali Khan, Shaghayegh Khanmohammadi, Moawiah Mohammad Khatatbeh, Mahalaqa Nazli Khatib, Maryam Khayamzadeh, Hamid Reza Khayat Kashani, Daniel Kheradmand, Feriha Fatima Khidri, Atulya Aman Khosla, Mohammad Ali Khosravi, Jagdish Khubchandani, Kwanghyun Kim, Yun Jin Kim, Yun Seo Kim, Ruth W Kimokoti, Adnan Kisa, Sezer Kisa, Shivakumar KM, Michail Kokkorakis, Ali-Asghar Kolahi, Farzad Kompani, Jianqiu Kong, Anastasios Georgios Konstas, Karel Kostev, Ashwin Laxmikant Kotmis, Sindhura Lakshmi Koulmane Laxminarayana, Irene Akwo Kretchy, Kewal Krishan, Raja Amir Hassan Kuchay, Mohammed Kuddus, Mukhtar Kulimbet, Dewesh Kumar, G Anil Kumar, Nithin Kumar, Vijay Kumar, Satyajit Kundu, Setor K Kunutsor, Pramod Kumar Kushawaha, Christina Yeni Yeni Kustanti, Tezer Kutluk, Ambily Kuttikkattu, Assylkhan Kuttybayev, Grace Kwakyewaa Kyei, Frank Kyei-Arthur, Ville Kytö, Carlo La Vecchia, Muhammad Awwal Ladan, Chandrakant Lahariya, Daphne Teck Ching Lai, Hanpeng Lai, Balzhan Lakanova, Dharmesh Kumar Lal, Judit Lám, Francesco Lanfranchi, Savita Lasrado, Mahrukh Latif, Paolo Lauriola, Basira Kankia Lawal, Huu-Hoai Le, Minh Huu Nhat Le, Nhi Huu Hanh Le, Thao Thi Thu Le, Caterina Ledda, Ivan Lee, Sang-woong Lee, Seung Won Lee, Shaun Wen Huey Lee, Wei-Chen Lee, Awol Yemane Legesse, James Leigh, Elyynna Leong, Ming-Chieh Li, Wang-Zhong Li, Wei Li, Xiaopan Li, Yongze Li, Zhengrui Li, Zhihui Li, Stephen S Lim, Queran Lin, Chaojie Liu, Gang Liu, Jue Liu, Liu Liu, Xiaofeng Liu, Xuefeng Liu, Erand Llanaj, Jaiios Lubinda, Angelina M Lutambi, Miltiadis D Lytras, Ellina Lytyvak, Hawraz Ibrahim M Amin, Zheng Feei Ma, Raymond Saa-Eru Maalman, Farzan Madadzadeh, Seyedeh Panid Madani, Alireza Mafi, Azzam A Maghazachi, Abdulahi Abdiwali Mahamed, Nozad Hussein Mahmood, Mansour Adam Mahmoud, Rashidul Alam Mahumud, Azeem Majeed, Abdelrahman M Makram, Omar M Makram, Konstantinos Christos C Makris, Satyaveni Malasala, Hadi Maleki-Kakelar, Kashish Malhotra, Ahmad Azam Malik, Iram Malik, Lesibana Anthony Malinga, Deborah Carvalho Malta, Vahid Mansouri, Marjan Mansourian, Mohammad Ali Mansournia, Lorenzo Giovanni Mantovani, Changkun Mao, Hamid Reza Marateb, Basma Hamed Marghani, Mirko Marino, Santi Martini, Miquel Martorell, Roy Rillera Marzo, Sammer Marzouk, Yasith Mathangasinghe, Medha Mathur, Fernanda Penido Matozinhos, Indu Liz Matthew, Martin McKee, Steven M McPhail, Enkeleint A Mechili, Jitendra Kumar Meena, Elahe Meftah, Riffat Mehboob, Asim Mehmood, Tesfahun Mekene Meto, Hadush Negash Meles, Addisu Melese, Max Alberto Mendez-Lopez, Walter Mendoza, Ritesh G Menezes, Dominik Menges, Endalkachew Worku Mengesha, Tara P Menon, Alexios-Fotios A Mentis, Sultan Ayoub Ayoub Meo, Atte Meretoja, Tuomo J Meretoja, Tomislav Mestrovic, Mohamed M M Metwally, Tomasz Miazgowski, Irmina Maria Michalek, Ted R Miller, Giuseppe Minervini, Mojgan Mirghafourvand, Awoke Misganaw, Sanjeev Misra, Prasanna Mithra, Yidnek Mogessie, Ashraf Mohamadkhani, Jama Mohamed, Mona Gamal Mohamed, Nouh Saad Mohamed, Karzan Abdulmuhsin Mohammad, Taj Mohammad, Sakineh Mohammad-Alizadeh-Charandabi, Abdolreza Mohammadi, Mohammad Kazem Mohammadi, Seyed Omid Mohammadi, Abdollah Mohammadian-Hafshejani, Ibrahim Mohammadzadeh, Zeinab Mohammadzadeh, Al-Kassim Hassan Mohammed, Mustapha Mohammed, Shafiu Mohammed, Amin Mohsenzadeh, Ali H Mokdad, Hossein Molavi Vardaniani, Sabrina Molinaro, Shaher Momani, Lorenzo Monasta, Mohammad Ali Moni, Yousef Moradi, Paula Moraga, Shane Douglas Morrison, Mahmoud M Morsy, Elias Mossialos, Fatemeh Motaharinezhad, Rohith Motappa, Kimia Mozahheb Yousefi, Ahmed Msherghi, Rabia Mubarak, Sumaira Mubarak, George Duke Mukoro, Admir Multa, Kavita Munjal, Efrén Murillo-Zamora, Ali Mushtaq, Saima Mushtaq, Shehzad Ibrahim Mustafa, Saravanan Muthupandian, Woojae Myung, Amin Nabavi, Ahamarshan Jayaraman Nagarajan, Gabriele Nagel, Pirouz Naghavi, Gurudatta Naik, Mukhammad David Naimzada, Firzan Nainu, Tapas Sadasivan Nair, Hastyar Hama Rashid Najmuldeen, Hae Sung Nam, Shumaila Nargus, Yvonne Narthey, Abdulqadir J Nashwan, Mahmoud Nassar, Zuhair S Natto, Javid Nauman, Nawsherwan , Biswa Prakash Nayak, Md Fahad Shahariar Nayon, Athare Nazri-Panjaki, Pacifique Ndishimye, Amanuel Tebabal Nega, Masoud Negahdary, Ionut Negoii,

- Chakib Nejari, Omid Nekouei, Gaurav Nepal, Henok Biresaw Netsere, Jean Claude Semuto Semuto Ngabonziza, Cuong Tat Nguyen, Dang Nguyen, Kieu Viet Nhi Nguyen, Nhan Nguyen, The Phuong Nguyen, Tuan Thanh Nguyen, Van Thanh Nguyen, Robina Khan Niazi, Luciano Nieddu, Nasrin Nikravangolsefid, Vikram Niranjana, Jean Marie Vianney Niyonsenga, Chukwudi A Nnaji, Lawrence Achilles Nnyanzi, Shuhei Nomura, Nurulamin M Noor, Syed Toukir Ahmed Noor, Mohammadamin Noorafrooz, Masoud Noroozi, Chisom Adaobi Nri-Ezedi, Fred Nugen, Dieta Nurrika, Chimezie Igwegbe Nzopotam, Ogochukwu Janet Nzopotam, Bogdan Oancea, Vincent Adeiza Obakachi, Ismail A Odetokun, Michael Safo Oduro, James Odhiambo Oguta, In-Hwan Oh, Hassan Okati-Aliabad, Sylvester Reuben Okeke, Akinkunmi Paul Okekunle, Osaretin Christabel Okonji, Andrew T Olagunju, Timothy Olusegun Olusegun Olanrewaju, Matthew Idowu Olatubi, Folorunsho Bright Omake, Hany A Omar, Goran Latif Omer, Abidemi E Omonisi, Sok King Ong, Obinna E Onwujekwe, Marcel Opitz, Michal Ordak, Verner N Orish, Atakan Orselik, Esteban Ortiz-Prado, Augustus Osborne, Alaa AM Osman, Samuel M Ostroff, Uchechukwu Levi Osuagwu, Elham H Othman, Oche Joseph Otokpa, Stanislav S Otvstavnov, Amel Ouyahia, Mayowa O Owolabi, Oladayo Ayobami Oyebanji, Kolapo Oyebola, Ilker Ozsahin, Mahesh P A, Alicia Padron-Monedero, Jagdish Rao Padubidri, Tamás Palicz, Sujogya Kumar Panda, Songhomitra Panda-Jonas, Deepshikha Pande Katara, Seithikurippu R Pandi-Perumal, Ke Pang, Georgios D Panos, Leonidas D Panos, Ioannis Pantazopoulos, Mario Virgilio Papa, Parinaz Paranjkhoo, Peyvand Parhizkar Roudsari, Romil R Parikh, Eun-Cheol Park, Maja Pasovic, Roberto Passera, Jay Patel, Riya Jayesh Patel, Shankargouda Patil, Apurba Patra, Hamidreza Pazoki Toroudi, Jarmila Pekarcikova, Umberto Pensato, Prince Peprah, Jeevan Pereira, Mario F P Peres, Simone Perna, Richard G Pestell, Olumuyiwa James Peter, Fanny Emily Petermann-Rocha, Hoang Tran Pham, Tung Thanh Pham, Daniela Pierannunzio, Julian David Pillay, Zahra Zahid Piracha, Saeed Pirouzpanah, Ramesh Poluru, Arjun Pon Avudaiappan, Maarten J Postma, Reza Pourbabaki, Farzad Pourghazi, Disha Prabhu, Jalandhar Pradhan, Peralam Yegneswaran Prakash, Chandra P Prasad, Akila Prashant, Elton Junio Sady Prates, Dimas Ria Angga Pribadi, Jagadeesh Puvvula, Asma Saleem Qazi, Suli Qiu, Karzan Qurbani, Hadi Raeesi Shahraki, Ata Rafiee, Alireza Rafiei, Pracheth Raghuvver, Haghbash Mohammed-Amin Rahim, Fryad Majeed Rahman, Md Mijanur Rahman, Mohammad Meshbahur Rahman, Mosiur Rahman, Muhammad Aziz Rahman, Amir Masoud Rahmani, Saeed Rahmani, Masoud Rahmati, Pramila Rai, Diego Raimondo, Ivano Raimondo, Sathish Rajaa, Rayan Rajabi, Mohammad Amin Rajizadeh, Majed Ramadan, Chitra Ramasamy, Shakthi Kumar Ramasamy, Pushkal Sinduvadi Ramesh, Zahra Ramezani, Juwel Rana, Rishabh Kumar Rana, Nemanja Rancic, Fatemeh Ranjbar Noei, Christopher Rao, Kumuda Rao, Mithun Rao, Sowmya J Rao, Wahid Rashedi, Mohammad-Mahdi Rashidi, Devarajan Rathish, Santosh Kumar Rauniyar, Ilari Rautalin, Salman Rawaf, Lal Rawal, Elrashdy Redwan, Sanika Rege, Ana Reis-Mendes, Stefano Restaino, Nazila Rezaei, Negar Rezaei, Nima Rezaei, Mohsen Rezaeian, Tércia Moreira Ribeiro da Silva, Maximiliano Ribeiro Ribeiro Guerra, Moattar Raza Rizvi, Thomas J Roberts, Hermano Alexandre Lima Rocha, João Rocha Rocha-Gomes, Thales Philippe Rodrigues da Silva, Ravi Rohilla, Peter Rohloff, Kevin T Root, Gholamreza Roshandel, Amirhossein Roshanshad, Himanshu Sekhar Rout, Guido Rovera, Nitai Roy, Sharmistha Roy, Korosh Saber, Maha Mohamed Saber-Ayad, Cameron John Sabet, Siamak Sabour, Basema Ahmad Saddik, Tarannom Sadegh, Mohammad Reza Saeb, Kanza Saeed, Mohd Saeed, Umar Saeed, Amene Saghazadeh, Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Amirhossein Sahebkar, Pragnan Monalisa Sahoo, Soumya Swaroop Sahoo, Mirza Rizwan Sajid, Mohamed A Saleh, Leili Salehi, Amir Salek Farrokhi, Marwa Rashad Salem, Sohrab Salimi, Pouria Samadi, Jayami Eshana Samaranyake, Yoseph Leonardo Samodra, Abdallah M Samy, Juan Sanabria, Milena M Santric-Milicevic, Made Ary Sarasmita, Aswini Saravanan, Saman Sargazi, Tanmay Sarkar, Gargi Sachin Sarode, Sachin C Sarode, Arash Sarveezad, Michele Sassano, Brijesh Sathian, Maheswar Satpathy, Reza Sattarpour, Jennifer Saulam, Monika Sawhney, Juhi Saxena, Benedikt Michael Schaarschmidt, Christophe Schinckus, Ione Jayce Ceola Schneider, Art Schuermans, Austin E Schumacher, Durairaj Sekar, Saravanan Sekaran, Mario Šekerija, Mohammad H Semreen, Ashenafi Kibret Sendekie, Pallav Sengupta, Yigit Can Senol, Subramanian Senthilkumaran, Dragos Serban, Yashendra Sethi, Seyed Mohammad Seyed Alshohadaei, Homa Seyedmirzaei, Allen Seylani, Maryam Shabany, Mahan Shafie, Muhammad Shahab, Ataollah Shahbadi, Samiah Shahid, Syed Ahsan Ahsan Shahid, Hamid R Shahsavari, Moyad Jamal Shahwan, Masood Ali Shaikh, Muhammad Aaqib Shamim, Elahe Shams, Mehran Shams-Beyranvand, Anas Shamsi, Alfia Shamsutdinova, Dan Shan, Mohd Shanawaz, Abhishek Shankar, Mohammed Shannawaz, Nigussie Tadesse Sharew, Amin Sharifan, Manoj Sharma, Rajesh Sharma, Ujjawal Sharma, Vishal Sharma, Shamee Shastri, Ramzi Shawahna, Maryam Shayan, Fateme Sheida, Samendra P Sherchan, Pavanchand H Shetty, Premalatha K Shetty, Ranjitha S Shetty, Suraj S Shetty, Mosa Shibani, Aminu Shittu, Velizar Shivarov, Zahra Shokati Eshkiki, Sinegugu Nosipho Shongwe, Sina Shool, Seyed Afshin Shorofi, Sunil Shrestha, Kerem Shuval, Yafei Si, Nicole R S Sibuyi, Emmanuel Edwar Siddig, Ahmed Kamal Siddiqi, Luis Manuel Lopes Rodrigues Silva, Amit Singh, Baljinder Singh, Harmanjit Singh, Jasvinder A Singh, Kalpana Singh, Mayank Singh, Paramdeep Singh, Prashant Kumar Singh, Puneetpal Singh, Satwinder Singh, Surjit Singh, Mukesh Kumar Sinha, Freddy Sitas, Dagne Feleke Siyoum, Anna Aleksandrovna Skryabina, Amanda E Smith, Farrukh Sobia, Solikhah Solikhah, Sameh S M Soliman, Aayushi Sood, Sandra Spearman, Bahadar S Srichawla, Suresh Kumar Srinivasamurthy, Devin Bailey Srivastava, Kurt Straif, Vetrisevan Subramaniam, Auwal Garba Suleiman, Muritala Odidi Suleiman Odidi, Muhammad Suleman, Desy Sulistiyorini, Anusha Sultan Meo, Zhong Sun, Vinay Suresh, Hani Susianti, Chandan Kumar Swain, Lukasz Szarpak, Sree Sudha T Y, Payam Tabae Damavandi, Rafael Tabarés-Seisdedos, Fatemeh Sadat Tabatabaei, Seyed Mohammad Tabatabaei, Ramin Tabibi, Mohammad Tabish, Seyed Reza Taha, Yasaman Taheri Abkenar, Moslem Taheri Soodejani, Jabeen Taiba, Iman M Talaat, Mircea Tampa, Jacques Lukenze Tamuzi, Ker-Kan Tan, Manoj Tanwar, Saba Tariq, Seyed Mohammad Tavangar, Birhan Tsegaw Taye, Abdelghani Tbakhi, Abainash Tekola, Mohamad-Hani Temsah, Dufera Rikitu Terefa, Wegen Beyene Tesfamariam, Enoch Teye-Kwadjo, Lakshmi Thangavelu, Rekha Thapar, Rasiah Thayakaran, Mahalakshmi Thayumana Sundaram, Hadiza Theyra-Enias, Nihal Thomas, Nikhil Kenny Thomas, Jansje Henny Vera Ticoalu, Tenaw Yimer Tiruye, Krishna Tiwari, Roman Topor-Madry, Adetunji T Toriola, Mathilde Touvier, Marcos Roberto Tovani-Palone, Eugenio Traini, Bach Xuan Tran, Ngoc Ha Tran, Quynh Thuy Huong Tran, Thang Huu Tran, Domenico Trico, Aristidis Tsatsakis, Abdul Rohim Tualeka, Mike Tuffour Amirikah, Lawrence Sena Tuglo, Atta Ullah, Saeed Ullah, Srikanth Umakanthan, Lawan Umar, Shehu Salihu Umar, Umar Muhammad Umar, Brigid Unim, Bhaskaran Unnikrishnan, Dinesh Upadhya, Asokan Govindaraj Vaithinathan, Omid Vakili, Jef Van den Eynde, Javad Varasteh, Shoban Babu Varthya, Siavash Vaziri, Balachandar Vellingiri, Madhur Verma, Massimiliano Veroux, Georgios-Ioannis Verras, Simone Villa, Gabriela Ines Villanueva, Francesco S Violante, Giuseppe Vizzelli, Sergey Konstantinovitch Vladimirov, Vasily Vlassov, Stein Emil Vollset, Elpida Vounzoulaki, Yasir Waheed, Cong Wang, Ruixuan Wang, Xing Wang, Yanzhong Wang, Muhammad Waqas, Paul Ward, Toyiba Hiyaru Wassie, Kosala Gayan Weerakoon, Ronny Westerman, Anggi Lukman Wicaksana, Dakshitha Praneeth Wickramasinghe, Nuwan Darshana Darshana Wickramasinghe, Karn Wijarnpreecha, Peter Willeit, Marcin W Wojewodzic, Axel Walter Wolf, Felicia Wu, James Fan Wu, Zenghong Wu, Qing Xia, Zhijia Xia, Lishun Xiao, Wanqing Xie, Libo Xu, Suowen Xu, Mingyang Xue, Mukesh Kumar Yadav, Galal Yahya, Amir Yarahmadi, Mohamed A Yassin, Sanni Yaya, Pengpeng Ye, Subah Abderehim Yesuf, Saber Yezli, Dehui Yin, Biksegn Asrat Yirdaw, Dong Keon Yon,

Naohiro Yonemoto, Mustafa Z Younis, Zabihollah Yousefi, Chuanhua Yu, Chun-Wei Yuan, Vesna Zadnik, Syed Nabeel Zafar, Manijeh Zaghampour, Fathiah Zakham, Nazar Zaki, Giulia Zamagni, Burhan Abdullah Zaman, Sojib Bin Zaman, Mohammad Javad Zare Sakhvidi, Michael Zastrozhin, Mohammed Zawiah, Mohammed G M Zeariya, Alemu Birara Zemariam, Sebastian Zensen, Jianrong Zhang, Jingya Zhang, Liqun Zhang, Xiaoyi Zhang, Zhi-Jiang Zhang, Yang Zhao, David X Zheng, Jinxin Zheng, Ming-Hua Zheng, Anthony Zhong, Claire Chenwen Zhong, Jiayan Zhou, Juexiao Zhou, Bin Zhu, Abzal Zhumagalituly, Magdalena Zielińska, Osama A Zitoun, Rafat Mohammad Zrieq, Mohammed Zuber, Sa'ed H Zyoud, Shafer H Zyoud, Theo Vos†, Christopher J L Murray†. \*First author. †Co-senior authors.

#### Affiliations

Please see appendix 3 (pp 8–41) for the affiliations for individual authors.

#### Contributors

Please see appendix 3 (pp 41–54) for more detailed information about individual author contributions to the research, divided into the following categories: managing the overall research enterprise; writing the first draft of the manuscript; primary responsibility for applying analytical methods to produce estimates; primary responsibility for seeking, cataloguing, extracting, or cleaning data; designing or coding figures and tables; providing data or critical feedback on data sources; developing methods or computational machinery; providing critical feedback on methods or results; drafting the manuscript or revising it critically for important intellectual content; and managing the estimation or publications process.

#### Declaration of interests

C Agostinis Sobrinho reports grants or contracts from the Fundação para a Ciência e a Tecnologia (CEECINST/00093/2021/CP2815/CT0001), outside the submitted work. R Ancuceanu reports consulting fees from AbbVie and Merck Romania; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from AbbVie, Laropharm, Reckitt, and Merck Romania; support for attending meetings or travel from Merck Romania and Reckitt, outside the submitted work. R Bai reports support for this Article from the Social Science Fund of Jiangsu Province (grant number 21G1D008). S Bhaskar reports grants or contracts from the Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology, Grant-in-Aid for Scientific Research (KAKENHI; grant 23KF0126), JSPS and the Australian Academy of Science, and JSPS International Fellowship (grant P23712); and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as: district chair of the Diversity, Equity, Inclusion & Belonging of Rotary District 9675 (Sydney, Australia); chair, founding member, and manager of the Global Health & Migration Hub Community, Global Health Hub Germany (Berlin, Germany); editorial board member of *PLOS One*, *BMC Neurology*, *Frontiers in Neurology*, *Frontiers in Stroke*, *Frontiers in Public Health*, *Journal of Aging Research*, and *Neurology International*, *Diagnostics*, & *BMC Medical Research Methodology*; member of the College of Reviewers, Canadian Institutes of Health Research, Government of Canada; Director of Research of World Headache Society (Bengaluru, India); expert adviser and reviewer of Cariplo Foundation (Milan, Italy); visiting director of National Cerebral and Cardiovascular Center, Department of Neurology, Division of Cerebrovascular Medicine and Neurology, Suita (Osaka, Japan); member of the Scientific Review Committee of Cardiff University Biobank (Cardiff, UK); chair of Rotary Reconciliation Action Plan; and Healthcare and Medical Adviser at Japan Connect (Osaka, Japan), outside the submitted work. M Carvalho reports other support from the Laboratório Associado para a Química Verde, University of Porto, Porto, Portugal, under the scope of the project UIDP/50006/2020, outside the submitted work. E C Dee reports support for this Article from the Prostate Cancer Foundation (Young Investigator Award) and the National Cancer Institute (P30 CA008748). A Faro reports support for this Article from the Brazilian National Council for Scientific and Technological Development. L M Force reports support for this Article from the Gates Foundation, St Jude Children's Research Hospital,

St Baldrick's Foundation; grants or contracts from Conquer Cancer Foundation, US National Institutes of Health (NIH) Loan Repayment Program; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid with the Lancet Oncology International Advisory Board, outside the submitted work. C Herteliu reports grants or contracts from the project "analysis of the impact of COVID-19 on the main demographic indicators in Romania and the Republic of Moldova by using econometric modeling" (code PN-IV-P8-8-3-ROMD-2023-0208) funded by the Romanian Ministry of Research, Innovation and Digitalization (MCID) through the Executive Agency for Higher Education, Research, Development and Innovation Funding, from a grant of the European Commission Horizon 4P-CAN (personalised cancer primary prevention research through citizen participation and digitally enabled social innovation), grants or contracts from the project "societal and economic resilience within multi-hazards environment in Romania" funded by the EU (NextgenerationEU and Romanian Government), under National Recovery and Resilience Plan for Romania (contract number 760050/23.05.2023' code PNRR-C9-I8-CF 267/ 29.11.2022) through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, Investment I8, grants or contracts from the project "a better understanding of socio-economic systems using quantitative methods from physics" funded by the EU (NextgenerationEU and Romanian Government), under National Recovery and Resilience Plan for Romania (contract number 760034/ 23.05.2023; code PNRR-C9-I8-CF 255/ 29.11.2022), through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, Investment I8, outside the submitted work. I Ilic reports support for this Article from the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (number 451-03-137/2025-03/200110). M Ilic reports support for this Article from the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (number 451-03-47/2023-01/200111). T Joo reports support for this Article from National Research, Development and Innovation Office in Hungary (RRF-2.3.1-21-2022-00006, Data-Driven Health Division of National Laboratory for Health Security). J Khubchandani reports grants or contracts from Merck Pharma and the National Science Foundation, outside the submitted work. J Kocarnik reports support for this Article from the Institute for Health Metrics and Evaluation (employee), the Gates Foundation (funding to institution), and the American Lebanese Syrian Associated Charities (funding to institution). A Konstas reports grants or contacts from Thea Pharmaceuticals, Omni Vision, Vianex, Santen, Intermed, and Bayer; consulting fees from Thea Pharmaceuticals and Santen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Thea Pharmaceuticals, Vianex, Intermed, and Esteve Pharmaceuticals; support for attending meetings or travel from Thea Pharmaceuticals, Vianex, and Intermed, outside the submitted work. K Krishan reports non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. M-C Li reports grants or contracts from the National Science and Technology Council, Taiwan (NSTC 113-2314-B-003-002) and the Higher Education Sprout Project of National Taiwan Normal University, outside the submitted work. W-Z Li reports support for this Article from the Postdoctoral Fellowship Program of China Postdoctoral Science Foundation (GZB20230179) and the Grant of State Key Laboratory of Respiratory Disease (SKLRD-Z-202401). J Liu reports support for this Article from the National Natural Science Foundation (72474005) and Beijing Natural Science Foundation (Z24004). E Lytvyak reports grants or contracts from University of Alberta, Advanz Pharma, WCB Alberta, and China Postdoctoral Science Foundation; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Alberta Obesity Society; other financial or non-financial support from University of Alberta and Alberta Health Services, outside the submitted work. H R Marateb reports grants or contracts from Universitat Politècnica de Catalunya, outside the submitted work. D Menges reports grants or contracts from Swiss Cancer Foundation, Dr Arnold U und Susanne Huggenberger-Bischoff Stiftung, one further, private, not-for-profit research foundation from

See Online for appendix 3

Switzerland (requested anonymity), all outside the submitted work. A-F Mentis reports grants or contracts from “MilkSafe: a novel pipeline to enrich formula milk using omics technologies”, a research co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call Research-Creat-Innovate (project code T2EDK-02222), as well as from ELIDEK (Hellenic Foundation for Research and Innovation, MIMS-860; both outside of the submitted work); payment or expert testimony as external peer-reviewer for Fondazione Cariplo, Italy; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as editorial board member for *Systematic Reviews* and *Annals of Epidemiology*, and as associate editor for *Translational Psychiatry*, outside the submitted work. S A Meo reports grants or contracts from Ongoing Research Funding Program (ORF-2025-47), King Saud University, Riyadh, Saudi Arabia, outside the submitted work. L Monasta reports support for this Article from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. S Nomura reports support for this Article from Ministry of Education, Culture, Sports, Science and Technology of Japan (24H00663), Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (JPMJPR22R8), and National Cancer Center Research and Development Fund (2024-A-14). B Oancea reports support for this Article from the Ministry of Research, Innovation and Digitalization through the Core Program of the National Research, Development and Innovation Plan 2022–2027 (project number PN 23–02–0101; contract number 7N/2023, PNRR/2022/C9/MCID/18 project 760096). F B Omage reports support for this Article from Sao Paulo Research Foundation (Fundação de Amparo à Pesquisa do Estado de São Paulo; grant number 2023/02691–2). S K Panda reports support for this Article from Siksha ‘O’ Anusandhan (deemed to be University); grants or contracts from File number 17–59/2023–24/CCRH/Tech./Coll./ICMR-Diabetes/960 as co-investigator; participation on a data safety monitoring board or advisory board as associate editor of Heliyon, outside the submitted work. S Rege reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as operational lead of International Society for Pharmacoeconomics and Outcomes Research’s Medication Adherence and Persistence’s Special Interest Group, review editor of Editorial Board of Pharmacoeconomics section within *Frontiers in Pharmacology*, Academic Editor of *PLOS ONE*’s Editorial Board, Editorial Board member of *Pain Management*, outside the submitted work. Y L Samodra reports grants or contracts from National Science and Technology Council, National Taiwan University and College of Public Health, Taipei Medical University; consulting fees from Jago Beasiswa; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as co-founder of Benang Merah Research Center, Indonesia, outside the submitted work. J Sanabria reports support for attending meetings or travel from Continuing Medical Education money from Marshall University School of Medicine, Department of Surgery; patents planned, issued or pending; participation on a data safety monitoring board or advisory board as vice-chair for research and quality assurance; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with several committees in National and International Societies, outside the submitted work. B M Schaarschmidt reports grants or contracts from Else Kröner-Fresenius Foundation Research, Deutsche Forschungsgemeinschaft, PharmaCept; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca and Boston Scientific; support for attending meetings or travel from Bayer, outside the submitted work. M Šekerija reports consulting fees from Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astellas, outside the submitted work. V Sharma reports other support from Directorate of Forensic Science Services (MHA)’s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University (Chandigarh, India), outside the submitted work. V Shivarov reports one patent from the Bulgarian Patent Office and other financial support from ICON plc, outside the submitted work. L Silva reports grants or contracts from

SPRINT, Sport Physical Activity and Health Research & Innovation Center, Polytechnic of Guarda, 6300–559 Guarda, Portugal; 2RISE-Health, Faculty of Health Sciences, University of Beira Interior, 6201–506 Covilhã, Portugal, outside the submitted work. J A Singh reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hullo, Horizon Pharmaceuticals, DINO-RA, ANI/Exeltis, USA, Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs, Adept Field Solutions, Clinical Care options, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, and Practice Point communications; and the NIH; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from the bureau of Simply Speaking; support for attending meetings or travel as a past steering committee member of OMERACT; participation on a data safety monitoring board or advisory board from the FDA Arthritis Advisory Committee; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as a past steering committee member of the OMERACT, an international organisation that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies; stock or stock options in Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, EnzoLytics, Seres Therapeutics, Tonix Pharmaceuticals Holding, Aebona Pharmaceuticals, and Charlotte’s Web Holdings, and previously owned stock options in Amarin, Viking and Moderna Pharmaceuticals, outside the submitted work. R Tabares-Seisdedos reports grants or contracts from Valencian Regional Government’s Ministry of Education (PROMETEO/CIPROM/2022/58) and from the Spanish Ministry of Science, Innovation and Universities (PID2021–129099OB-I00), outside the submitted work (the funders were not involved in the design of the manuscript or decision to submit the manuscript for publication, nor will they be involved in any aspect of the study’s conduct). J H V Ticoalu reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as co-founder of Benang Merah Research Center, Indonesia, outside the submitted work. D Trico reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Eli Lilly, Novo Nordisk; Support for attending meetings or travel from AstraZeneca; participation on a data safety monitoring board or advisory board with Amarin, Boehringer Ingelheim, Novo Nordisk; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid EASD Early Career Academy and EASD Committee on Clinical Affairs; receipt of equipment, materials, drugs, medical writing, gifts or other services paid to the institution from Abbott and PharmaNutra, outside the submitted work. E Vounzoulaki reports grants or contracts from NIHR DSE Award (until July 2026), outside the submitted work. P Willeit reports consulting fees from Novartis Pharmaceuticals, outside the submitted work. J F Wu reports grants or contracts from the National Heart, Lung, and Blood Institute (R38HL167238) and acknowledges previous funding from the American Society of Hematology Hematology Opportunities for the Next Generation of Research Scientists (HONORS) Award, outside the submitted work. S N Zafar reports grants or contracts from the NIH/NCI Early-Stage Surgeon Scientist Program (grant P30 CA014520–48S4), outside the submitted work. M Zielińska reports other support as an Alexion, AstraZeneca Rare Disease employee, outside the submitted work.

#### Data sharing

To download the data used in these analyses, please visit the Global Health Data Exchange (<https://ghdx.healthdata.org/gbd-2023>).

#### Acknowledgments

Research reported in this publication was supported by the Gates Foundation (OPP1152504), St Jude Children’s Research Hospital, and St Baldrick’s Foundation. We thank the many cancer registries and vital registration systems around the world that contributed data to the GBD 2023 study and that continually work to generate data on cancer burden. Directly observed cancer data are required to generate estimates of global cancer burden, and cancer surveillance systems are critical to support as part of working towards an improved understanding of global

cancer burden in the future. We are also grateful for the contributions of the GBD collaborator network, who are working across the world to improve cancer outcomes. Finally, we wish to acknowledge the individuals and families impacted by cancer; each estimate in our analysis is composed of unique and valuable lives, and we should not lose sight of this among the sheer volume of the burden. We hope these estimates prove to be useful in our collective efforts to reduce cancer burden now and in the future.

## References

- Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *JAMA Oncol* 2022; 8: 420–44.
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; 396: 1204–22.
- Ginsburg O, Vanderpuye V, Beddoe AM, et al. Women, power, and cancer: a Lancet Commission. *Lancet* 2023; 402: 2113–66.
- Ngwa W, Addai BW, Adewole I, et al. Cancer in sub-Saharan Africa: a Lancet Oncology Commission. *Lancet Oncol* 2022; 23: e251–312.
- Lawler M, Davies L, Oberst S, et al. European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission. *Lancet Oncol* 2023; 24: e11–56.
- Atun R, Bhakta N, Denburg A, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. *Lancet Oncol* 2020; 21: e185–224.
- Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, et al. Progress and remaining challenges for cancer control in Latin America and the Caribbean. *Lancet Oncol* 2015; 16: 1405–38.
- Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. *Lancet Oncol* 2011; 12: 933–80.
- Rubin G, Berendsen A, Crawford SM, et al. The expanding role of primary care in cancer control. *Lancet Oncol* 2015; 16: 1231–72.
- WHO. The global initiative for childhood cancer. <https://www.who.int/initiatives/the-global-initiative-for-childhood-cancer> (accessed Oct 11, 2024).
- WHO. The global breast cancer initiative. <https://www.who.int/initiatives/global-breast-cancer-initiative> (accessed Oct 11, 2024).
- WHO. Cervical cancer elimination initiative. <https://www.who.int/initiatives/cervical-cancer-elimination-initiative> (accessed Oct 11, 2024).
- WHO. SDG target 3.4: noncommunicable diseases and mental health: by 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being. <https://www.who.int/data/gho/data/themes/topics/indicator-groups/indicator-group-details/GHO/sdg-target-3.4-noncommunicable-diseases-and-mental-health> (accessed Oct 11, 2024).
- NCD Countdown 2030 collaborators. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4. *Lancet* 2020; 396: 918–34.
- Teglia F, Angelini M, Astolfi L, Casolari G, Boffetta P. Global association of COVID-19 pandemic measures with cancer screening: a systematic review and meta-analysis. *JAMA Oncol* 2022; 8: 1287–93.
- WHO. The impact of the COVID-19 pandemic on noncommunicable disease resources and services: results of a rapid assessment. World Health Organization, 2020.
- Riera R, Bagattini AM, Pacheco RL, Pachito DV, Roitberg F, Ilbawi A. Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review. *JCO Glob Oncol* 2021; 7: 311–23.
- Angelini M, Teglia F, Astolfi L, Casolari G, Boffetta P. Decrease of cancer diagnosis during COVID-19 pandemic: a systematic review and meta-analysis. *Eur J Epidemiol* 2023; 38: 31–38.
- Dos-Santos-Silva I, Gupta S, Orem J, Shulman LN. Global disparities in access to cancer care. *Commun Med (Lond)* 2022; 2: 31.
- Molassiotis A, Yates P, Li Q, et al. Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study. *Ann Oncol* 2017; 28: 2552–58.
- Beaglehole R, Bonita R, Magnusson R. Global cancer prevention: an important pathway to global health and development. *Public Health* 2011; 125: 821–31.
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2024; 74: 229–63.
- GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. *Lancet* 2025; published online Oct 12. [https://doi.org/10.1016/S0140-6736\(25\)01637-X](https://doi.org/10.1016/S0140-6736(25)01637-X).
- GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. *Lancet* 2025; published online Oct 12. [https://doi.org/10.1016/S0140-6736\(25\)01917-8](https://doi.org/10.1016/S0140-6736(25)01917-8).
- GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; 403: 2133–61.
- GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; 403: 2100–32.
- GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; 403: 2204–56.
- Institute for Health Metrics and Evaluation. Protocol for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). <https://www.healthdata.org/research-analysis/about-gbd/protocol> (accessed Jan 11, 2024).
- Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. *Lancet* 2016; 388: e19–23.
- WHO. International Statistical Classification of Diseases and Related Health Problems, 10th revision, 2nd ed. World Health Organization, 2004.
- The World Bank. World Bank country and lending groups. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> (accessed Oct 11, 2024).
- Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. *Popul Health Metr* 2012; 10: 1.
- GBD 2023 Demographics Collaborators. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023. *Lancet* 2025; published online Oct 12. [https://doi.org/10.1016/S0140-6736\(25\)01330-3](https://doi.org/10.1016/S0140-6736(25)01330-3).
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021; 372: n71.
- Zheng P, Barber R, Sorensen RJD, Murray CJL, Aravkin AY. Trimmed constrained mixed effects models: formulations and algorithms. *J Comput Graph Stat* 2021; 30: 544–56.
- WHO. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. World Health Organization, 2013.
- WHO. WHO Discussion Paper on the development of an implementation roadmap 2023–2030 for the WHO Global Action Plan for the prevention and control of NCDs 2023–2030. World Health Organization, 2021.
- Casolino R, Mikkelsen B, Ilbawi A. Elevating cancer on the global health agenda: towards the fourth high-level meeting on NCDs 2025. *Ann Oncol* 2024; 35: 933–35.

- 39 Institute for Health Metrics and Evaluation. Financing global health 2023: the future of health financing in the post-pandemic era. May 14, 2024. <https://www.healthdata.org/research-analysis/library/financing-global-health-2023-future-health-financing-post-pandemic-era> (accessed Oct 11, 2024).
- 40 Global Burden of Disease 2021 Health Financing Collaborator Network. Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026. *Lancet Glob Health* 2023; **11**: e385–413.
- 41 Khan G, Fitzmaurice C, Naghavi M, Ahmed LA. Global and regional incidence, mortality and disability-adjusted life-years for Epstein–Barr virus-attributable malignancies, 1990–2017. *BMJ Open* 2020; **10**: e037505.
- 42 Nugent R. A chronology of global assistance funding for NCD. *Global Heart* 2016; **11**: 371–74.
- 43 Jaiobaeva K, Falconer J, Loffreda G, Arakelyan S, Witter S, Ager A. An analysis of policy and funding priorities of global actors regarding noncommunicable disease in low- and middle-income countries. *Global Health* 2021; **17**: 68.
- 44 Allemami C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet* 2018; **391**: 1023–75.
- 45 Soerjomataram I, Cabasag C, Bardot A, et al. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries. *Lancet Oncol* 2023; **24**: 22–32.
- 46 Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. *Lancet Oncol* 2019; **20**: 1493–505.
- 47 Oar A, Moraes FY, Romero Y, Ilbawi A, Yap ML. Core elements of national cancer control plans: a tool to support plan development and review. *Lancet Oncol* 2019; **20**: e645–52.
- 48 Romero Y, Trapani D, Johnson S, et al. National cancer control plans: a global analysis. *Lancet Oncol* 2018; **19**: e546–55.
- 49 Gelband H, Sankaranarayanan R, Gauvreau CL, et al. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition. *Lancet* 2016; **387**: 2133–44.
- 50 WHO. NCD best buys. 2018. <http://www.emro.who.int/noncommunicable-diseases/publications/factsheets.html> (accessed Oct 11, 2024).
- 51 WHO. More ways, to save more lives, for less money: World Health Assembly adopts more Best Buys to tackle noncommunicable diseases. May 26, 2023. <https://www.who.int/news/item/26-05-2023-more-ways-to-save-more-lives-for-less-money---world-health-assembly-adopts-more-best-buys-to-tackle-noncommunicable-diseases> (accessed Sept 12, 2025).
- 52 Bobby JM, Rajappa S, Mathew A. Financial toxicity in cancer care in India: a systematic review. *Lancet Oncol* 2021; **22**: e541–49.
- 53 Kimman M, Jan S, Yip CH, et al, and the ACTION Study Group. Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries. *BMC Med* 2015; **13**: 190.
- 54 Smith GL, Banegas MP, Acquati C, et al. Navigating financial toxicity in patients with cancer: A multidisciplinary management approach. *CA Cancer J Clin* 2022; **72**: 437–53.
- 55 Kazzi B, Chino F, Kazzi B, et al. Shared burden: the association between cancer diagnosis, financial toxicity, and healthcare cost-related coping mechanisms by family members of non-elderly patients in the USA. *Support Care Cancer* 2022; **30**: 8905–17.
- 56 Ritter J, Allen S, Cohen PD, et al. Financial hardship in families of children or adolescents with cancer: a systematic literature review. *Lancet Oncol* 2023; **24**: e364–75.
- 57 Jan S, Laba T-L, Essue BM, et al. Action to address the household economic burden of non-communicable diseases. *Lancet* 2018; **391**: 2047–58.
- 58 Watkins DA, Jamison DT, Mills A, et al. Universal Health Coverage and essential packages of care. In: Jamison DT, Gelband H, Horton S, et al, eds. Disease control priorities: improving health and reducing poverty, 3rd edn. The International Bank for Reconstruction and Development, 2017.
- 59 Tucker-Seeley R, Abu-Khalaf M, Bona K, et al. Social determinants of health and cancer care: an ASCO policy statement. *JCO Oncol Pract* 2024; **20**: 621–30.
- 60 Lunn RM, Mehta SS, Jahnke GD, Wang A, Wolfe MS, Berridge BR. Cancer hazard evaluations for contemporary needs: highlights from new national toxicology program evaluations and methodological advancements. *J Natl Cancer Inst* 2022; **114**: 1441–48.
- 61 Kickbusch I, Allen L, Franz C. The commercial determinants of health. *Lancet Glob Health* 2016; **4**: e895–96.
- 62 US National Cancer Institute, WHO. The economics of tobacco and tobacco control. National Cancer Institute Tobacco Control Monograph Series 21. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, World Health Organization, 2016.
- 63 WHO. MPOWER. <https://www.who.int/initiatives/mpower> (accessed Oct 11, 2024).
- 64 Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. *N Engl J Med* 2020; **383**: 1340–48.
- 65 WHO. Human papillomavirus vaccines: WHO position paper, December 2022. World Health Organization, 2022.
- 66 Sankaranarayanan R. Screening for cancer in low- and middle-income countries. *Ann Glob Health* 2014; **80**: 412–17.
- 67 Sedhom R, Gyawali B. When is a suboptimal approach to cancer screening better than none? *AMA J Ethics* 2020; **22**: E93–101.
- 68 Kontis V, Mathers CD, Rehm J, et al. Contribution of six risk factors to achieving the 25x25 non-communicable disease mortality reduction target: a modelling study. *Lancet* 2014; **384**: 427–37.
- 69 WHO. Closing the gap in a generation: health equity through action on the social determinants of health. World Health Organization, 2008.
- 70 WHO International Agency for Research on Cancer. Global Cancer Observatory: cancer today. [https://gco.iarc.fr/today/en/dataviz/tables?mode=cancer&group\\_populations=1&multiple\\_populations=1&types=1](https://gco.iarc.fr/today/en/dataviz/tables?mode=cancer&group_populations=1&multiple_populations=1&types=1) (accessed Oct 11, 2024).
- 71 Naghavi M, Richards N, Chowdhury H, et al. Improving the quality of cause of death data for public health policy: are all ‘garbage’ codes equally problematic? *BMC Med* 2020; **18**: 55.
- 72 WHO International Agency for Research on Cancer. About the GICR: The Global Initiative for Cancer Registry Development. <https://gicr.iarc.fr/about-the-gicr/> (accessed Oct 11, 2024).
- 73 Runggay H, Shield K, Charvat H, et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. *Lancet Oncol* 2021; **22**: 1071–80.
- 74 Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. *Lancet Oncol* 2015; **16**: 36–46.
- 75 WHO International Agency for Research on Cancer. Global Cancer Observatory: cancer tomorrow. [https://gco.iarc.fr/tomorrow/en/dataviz/tables?types=1&mode=cancer&group\\_populations=1&years=2050](https://gco.iarc.fr/tomorrow/en/dataviz/tables?types=1&mode=cancer&group_populations=1&years=2050) (accessed July 19, 2024).
- 76 Thrush A, Hyder AA. The neglected burden of caregiving in low- and middle-income countries. *Disabil Health J* 2014; **7**: 262–72.
- 77 Johnson SE, Samson M. Cancer stigma: the need for policy and programmatic action. *J Natl Cancer Inst Monogr* 2024; **2024**: 45–50.
- 78 Guida F, Kidman R, Ferlay J, et al. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. *Nat Med* 2022; **28**: 2563–72.